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1. ABSTRACT 
Recent revolutionary progress in human genomics is reshaping the approach to therapy 
and diagnosis. Nucleic acid–based testing is the major diagnostic tool not only in the 
setting of inherited genetic disease but in a wide variety of neoplastic and infectious 
processes. The “Reverse Line Blot” (RLB) is a robust method for the molecular 
characterization of several disorders. It is a simple technique that can be used in 
diagnostic routine also by small laboratories, because the request instruments are few 
and not expensive. 
The aim of our project is to exploit the potential of this method for assessment of two 
different disorders: a rare hereditary disease (atypical cystic fibrosis) and a hepatic 
pathology caused by the Hepatitis C Virus (HCV).  
In the first part of the study we explore the potentiality of RLB in detecting known 
genetic mutations in the human genome and our interest was focused on atypical CF. 
This pathology is characterized by cystic fibrosis (CF) mild symptoms, involvement of few 
organs, and only one or none mutations in the CFTR gene. This phenotypic heterogeneity 
could be explained by modifier genes of the CFTR gene, such as the genes coding for the 
Epithelial Sodium Channel (ENaC). During this project, we developed a new RLB 
molecular assay for detection of nine already described variations in the ENaC genes, 
involved in CF-like disorders. The performance of the method were evaluated analyzing 
208 patient samples, with respiratory or pancreatic manifestations, and 169 true healthy 
individuals as control group. Among the atypical CF patients, with one or none CFTR 
mutations and showing respiratory symptoms, we found seven ENaC different variants: 
the mutations p.S82C-SCNN1B, p.P267L-SCNN1B, p.G294S-SCNN1B, p.E539K-SCNN1B, 
p.1670-2A>G-SCNN1B, and the polymorphisms p.W493R-SCNN1A and p.R181W-
SCNN1A. In particular, p.P267L-SCNN1B, p.G294S-SCNN1B, p.E539K-SCNN1B, p.1670-
2A>G-SCNN1B showed a frequency significantly higher in patients rather in controls 
(P<0.05), while for the other variants there was no significantly differences between the 
two groups. Instead, in the group of patients with pancreatitis, we found only 3 variants 
(p.W493R-SCNN1A, p.R181W-SCNN1A, p.S82C-SCNN1B), but without significantly 
differences between patient group and controls. 
In the second part of the study, we explore the potentiality of RLB in the identification 
of the genotypic strand of Hepatitis C virus. HCV is a single-strand positive RNA virus, 
which strains can be classified into 7 genotypes. Knowing HCV genotype is essential for 
the therapeutic management and it is related to antiviral therapy outcome. The 5’ 
untranslated region (5’ UTR) of the HCV genome is used as target region in most 
genotyping test. However it is not enough informative for subtyping genotype 1, 
distinguishing 1a and 1b, and for discrimination of genotypes 1 from 6 (subtypes c-l). 
During this project, we developed a molecular assay for HCV genotyping, which allows 
reliable distinction between genotypes and subtypes. The method is based on reverse-
transcription of two viral regions (5’UTR and core), followed by RLB genotyping.  For the 
performance evaluation of the developed assay, 283 serum samples were collected: 212 
HCV positive, 71 HCV negative and 8 synthetic samples (representative of less common 
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genotypes 5, 6 and 7a). Another CE-IVD genotyping assay and the sequencing of NS5b 
viral region were used as reference methods. Our results showed that the use of two 
viral regions for genotyping allows a better discrimination of subtypes 1a and 1b. Among 
145 genotype 1 samples, 22 samples (whose subtyping 1a or 1b was not solved by the 
use of the sole 5’UTR) were correctly typed as 1a or 1b. The genotyping of other 8 
samples, previously incorrectly subtyped, were solved. Moreover, the new assay has 
successfully genotyped 5 samples with genotype 6 that were misdiagnosed as genotype 
1 with the analysis of 5’UTR. Our assay showed a diagnostic specificity of 100% and a 
sensibility of 98.6% both at genotype and subtype levels, in a range of viral loads 
between 1 x 103 and 6 x 107 IU/mL.  
Therefore, combined analysis of both 5’UTR and core regions could be very useful for a 
better discrimination between subtypes 1a and 1b, and between genotypes 1 and 6, 
leading to a more powerful instrument for the application of appropriate therapeutic 
regimen. 
In conclusion, this work has demonstrated that RLB is a robust method for the 
management of several diseases, requiring a genetic characterization. However, genetic 
knowledge about target disorders must to be well defined. 
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RIASSUNTO 
I recenti progressi nel campo della genomica umana hanno fortemente influenzato 
l’approccio diagnostico e terapeutico alle patologie. La biologia molecolare si è 
affermata come strumento di elezione per la diagnosi non solo di malattie ereditarie ma 
anche di una grande varietà di processi neoplastici ed infettivi. Tra le metodologie di 
questa disciplina, il “Reverse Line Blot” (RLB) occupa un posto di rilievo, grazie alla sua 
versatilità. E’ una tecnologia molto semplice e può essere utilizzata per la routine 
diagnostica anche da piccoli laboratori, in quanto la strumentazione necessaria è 
limitata e non eccessivamente costosa. L'obiettivo del nostro progetto è stato quello di 
sfruttare le potenzialità di questa tecnologia applicandola allo studio di due diverse 
patologie: una malattia ereditaria (fibrosi cistica atipica) ed una patologia epatica 
causata dall’infezione del virus dell'epatite C (HCV). 
Nella prima parte dello studio, abbiamo esplorato le potenzialità della tecnologia RLB 
per l’identificazione di mutazioni genetiche note, concentrandoci sullo studio della 
fibrosi cistica atipica. Si tratta di una patologia caratterizzata dagli stessi sintomi della 
fibrosi cistica (FC), che si presentano però in forma più lieve, con il coinvolgimento 
solamente di alcuni organi, ed una o nessuna mutazione nel gene CFTR. Questa 
eterogeneità fenotipica può essere dovuta all’azione di geni modificatori di CFTR, come, 
per esempio, quelli che codificano il canale epiteliale del sodio (ENaC). Nel corso di 
questo progetto è stato sviluppato un nuovo test molecolare basato sulla metodologia 
RLB, per la rilevazione di 9 varianti nei geni ENaC, coinvolte nella FC atipica e 
precedentemente descritte da altri gruppi. Le performance del metodo sono state 
valutate analizzando 208 campioni di pazienti con sintomi respiratori o manifestazioni 
pancreatiche, e 169 individui sani del gruppo di controllo. Tra i pazienti con sintomi 
respiratori e affetti da FC atipica, recanti una o nessuna mutazione CFTR, abbiamo 
trovato 7 diverse varianti ENaC: le mutazioni p.S82C-SCNN1B, p.P267L-SCNN1B, 
p.G294S-SCNN1B, p.E539K-SCNN1B, p.1670-2A>G-SCNN1B, ed i polimorfismi p.W493R-
SCNN1A e p.R181W-SCNN1A. In particolare, p.P267L-SCNN1B, p.G294S-SCNN1B, 
p.E539K-SCNN1B, p.1670-2A>G-SCNN1B mostravano una frequenza significativamente 
più alta nei pazienti rispetto ai controlli (p <0,05), mentre per le altre varianti non 
abbiamo rilevato differenze significative tra i 2 gruppi. Invece nel gruppo di pazienti con 
pancreatiti, abbiamo identificato 3 varianti ENaC (p.W493R-SCNN1A, p.R181W-SCNN1A, 
p.S82C-SCNN1B), ma le loro frequenze non erano significativamente diverse tra il 
gruppo degli affetti e quello dei controlli.  
Nella seconda parte dello studio, abbiamo esplorato le potenzialità della tecnologia RLB 
per l’identificazione dei ceppi genotipici del virus dell’epatite C.  HCV è un virus a RNA, 
a singolo filamento positivo, i cui ceppi possono essere classificati in 7 genotipi. 
L’identificazione del genotipo di HCV è essenziale per la gestione terapeutica ed è 
correlato all’esito della terapia antivirale. La regione non tradotta al 5’ (5' UTR) del 
genoma di HCV viene utilizzata come target nella maggior parte dei test di 
genotipizzazione. Tuttavia tale regione, sebbene altamente conservata, si è rivelata non 
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sufficientemente informativa per la distinzione dei sottotipi HCV 1a e 1b, e per la 
discriminazione dei genotipi 1 dal genotipo 6 (sottotipi da c a l).  
Nel corso di questo progetto è stato sviluppato un test molecolare per la 
genotipizzazione di HCV, che consente una buona distinzione tra genotipi e sottotipi. Il 
metodo è basato sulla retrotrascrizione di due regioni virali (5'UTR e core), seguita dalla 
genotipizzazione in RLB. Per la valutazione delle performance del nostro test sono stati 
analizzati 283 campioni di siero: 212 erano positivi per HCV, 71 erano negativi, mentre 
8 erano campioni sintetici, e corrispondevano ai rari genotipi 5, 6 a 7a. Come metodi di 
riferimento sono stati utilizzati un dispositivo CE-IVD che analizza la sola regione 5’UTR 
ed il sequenziamento della regione virale NS5b. 
I risultati ottenuti hanno dimostrato che l'utilizzo di due regioni virali per la 
genotipizzazione consente una migliore discriminazione dei sottotipi 1a e 1b. Su un 
totale di 145 isolati con genotipo 1, 22 campioni, non sottotipizzati mediante la sola 
analisi della 5’UTR, sono stati correttamente tipizzati come 1a o 1b grazie all’analisi 
combinata 5’UTR e core. Inoltre il nostro metodo ha permesso di effettuare la 
sottotipizzazione di altri 8 campioni, per i quali l’analisi della sola 5’UTR aveva assegnato 
una tipizzazione non corretta. Per quanto riguarda i campioni con genotipo 6, il test 
sviluppato è stato in grado di tipizzarne correttamente 5, che erano stati erroneamente 
definiti come genotipo 1 mediante l’analisi della sola regione 5’UTR. Il nostro test ha 
evidenziato una specificità diagnostica del 100% e una sensibilità del 98,6%, sia a livello 
di genotipizzazione che di sottotipizzazione, in un range di carica virale compreso tra 1 
x 103 and 6 x 107 UI/mL. Pertanto, l'analisi combinata delle due regioni 5'UTR e core 
determina un’accurata discriminazione tra i sottotipi 1a e 1b, e tra i genotipi 1 e 6, e 
diventa uno strumento molto importante per l'applicazione del regime terapeutico più 
appropriato. 
In conclusione, il nostro lavoro ha dimostrato che la tecnologia RLB è un metodo 
affidabile per la diagnosi di molte patologie, per le quali si renda necessaria una 
caratterizzazione genetica. Va però sottolineato che dispositivi basati sulla metodologia 
RLB possono diventare validi strumenti diagnostici solo per malattie ben caratterizzate 
da un punto di vista genetico. 
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2. FOREWORD 
This project concerns about the work that I carried out at AB ANALITICA s.r.l. in the 
context of an advanced apprenticeship program for the acquisition of a Ph. D. 
qualification. AB ANALITICA is a certified company established in 1990 and specialized 
in the design, development, production and trade of in vitro medical diagnostic devices 
(IVD) of diagnostic molecular systems. Fields of interest are microbiology, virology, onco-
hematology and genetics. 
Recent revolutionary progress in human genomics is reshaping the approach to therapy 
and diagnosis. Nucleic acid–based testing is becoming a crucial diagnostic tool not only 
in the setting of inherited genetic disease, but in a wide variety of neoplastic and 
infectious processes. Following diagnosis, molecular testing can help guide to 
appropriate therapy by identifying specific therapeutic targets of several newly tailored 
drugs, thus playing an integral role in the application of pharmacogenomics. Molecular 
diagnostics provides the necessary support for any successful application of gene 
therapy or biologic response modifiers. It offers a great tool for assessing disease 
prognosis and therapy response and detecting minimal residual disease [1]. 
Molecular diagnostic techniques for viral testing have experimented a rapid 
development during last years, and have been introduced in the majority of laboratories 
as a new way for the diagnosis of human pathogens like viruses.  The use of amplification 
techniques such as polymerase chain reaction (PCR), real-time PCR or reverse line blot 
(RLB) for virus detection, genotyping and quantification have some advantages like high 
sensitivity and reproducibility, as well as a broad dynamic range. 
Molecular diagnostic methods for the inherited genetic disease can be divided in 2 main 
groups: direct techniques that test for known mutations (genotyping) and indirect 
techniques that scan for any mutation in a particular target region (mutation scanning). 
There are several well-known genotyping and scanning methods in routine diagnostic 
use. 
A direct technique for genotyping is the Reverse Line (or Dot) Blot (RLB or RDB), a 
relatively simple and less expensive method that can be used in diagnostic routine also 
by small laboratories. Reverse allele specific oligonucleotide assays provide a robust 
method for the molecular characterization of several disorders, caused by genetic 
mutations or by infective agents. RLB rely upon highly multiplexed PCR reactions 
containing biotinylated primers and upon the hybridization between amplification 
products and oligonucleotides bound on a nylon or nitrocellulose membrane. The 
detection system is based on a colorimetric reaction, catalysed by strepatvidin alkaline 
phosphatase or by streptavidin horseradish peroxidase. 
Briefly the protocol involves the extraction of DNA or RNA from the specimen and then 
the selectively amplification of the sample. A strip is coated with highly specific probes, 
which are complementary to the amplified nucleic acid sequences. The amplification 
products are chemically denatured, and they are specifically bound by the 
complementary probes during the hybridization step. Non-specifically bound products 
are removed in subsequent washing steps. In the following step, bound product is 
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labelled with the enzyme alkaline phosphatase and made visible by a colorimetric 
reaction. In this way, a specific band pattern appears on the strip (fig. 1-2).  
 
 
The technique can be utilized in a number of ways. Multiple probes can be designed to 
detect sequence variation within a single amplified product, or multiple targets can be 
amplified simultaneously, with one (or more) probes used for subsequent detection. A 
combination of both approaches can also be used within a single assay. The ability to 
include multiple probes for a single target sequence makes the assay highly specific. The 
flexibility of the method allows its use for a wide range of applications. 
The entire procedure from patient’s sample to result usually requires less than 1 day.  
Large numbers of individuals can be rapidly screened for multiple targets using this 
technology. The method is simple, rapid, and generally shows high sensitivity and 
specificity. Commercial instruments are available, that automate the hybridization and 
colour development. In addition, scanning software can capture the probe reactivity 
pattern and interpret it in terms of a genotype. 
RLB is rapidly becoming a standard molecular tool for diagnostic and epidemiological 
studies in an increasing number of laboratories all over the world, thanks to its peculiar 
features. 
 
 
RLB is a method that can be applied to several fields, such as human genetics, 
microbiology and parasitology.   
Fig. 1 Schematic representation of the reverse line blot 
technique. 
Fig. 2 Image of a developed strip. 
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2. AIM OF THE STUDY 
The aim of our project was the development of RLB tests and the evaluation of their 
application in the management of diseases, requiring a genetic characterization. 
We focused our attention on two different disorders, one regarding a hereditary disease 
and the other caused by an infectious agent. 
In the first part of the study, we explored the potentiality of RLB in detecting known 
genetic mutations in the human genome and our interest was focused on atypical cystic 
fibrosis. This is a rare genetic disease, not well genetically characterized and probably 
related to the presence of mutations in the ENaC genes. Knowledge about causative 
mutations, in this case, is very limited. 
In the second part of the study, we evaluated usefulness of RLB in the identification of 
the genotypic strand of Hepatitis C virus (HCV), an infectious agent that causes chronic 
hepatitis, cirrhosis and hepatocellular carcinoma. In this case, information about HCV 
genotypes is widely defined. 
Our purpose was to evaluate potentiality of RLB in the application to clinical diagnosis 
and therapy management of both diseases, different not only in the transmission way 
but also in the genetic knowledge available for each one. 
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3. PART I: ATYPICAL CYSTIC FIBROSIS 
3.1. INTRODUCTION 
Cystic fibrosis (CF) is the most common autosomal disorder in Caucasians, with a 
frequency of about 1 in 2500 live births [2]. 
This pathology affects the chloride transport of polarized epithelia cells. Abnormally 
viscous secretions in the airways of the lungs cause obstructions that lead to 
inflammation and subsequent chronic bacterial infections by pathogens such as 
Pseudomonas aeruginosa, Staphylococcus aureus and Burkholderia cepacia. Finally, the 
chronic inflammation lead to tissue damage and destruction of the organ system; 
obstructive lung disease is currently the primary cause of morbidity and is responsible 
for about 80% of mortality in these patients. 
Other organ systems containing epithelia, such as ducts of the pancreas, the sweat 
gland, biliary duct of the liver, the male reproductive tract and the intestine, are also 
affected. Loss of pancreatic exocrine function results in malnutrition and poor growth, 
which leads to death in the first decade of life for most untreated individuals [3]. 
98% of men with cystic fibrosis are infertile, with aspermia secondary to atretic or absent 
vasa deferentia and dilated or absent seminal vesicles. Female reproductive function is 
normal, although cervical mucus can be dehydrated, which might impair fertility [2]. 
3.1.1. CFTR  
Cystic fibrosis is caused by mutations in the cystic fibrosis transmembrane regulator 
(CFTR) gene, which has been identified in the 1989 by positional cloning. It is located on 
long arm of chromosome 7 and it is composed by 27 exons, spanning over 230 kb [4] 
(fig. 3). 
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The predicted structure of the CFTR, based on aminoacid sequence, is composed by 
twelve transmembrane domains, two nucleotide binding motifs and a regulatory R 
domain in the center [6]. These topological features associated the CFTR with the 
members of the ABC (ATP binding cassette) superfamily of transporters (fig. 4). 
Protein purification and gene transfer studies have demonstrated that CFTR functions 
as a chloride channel regulated by cyclic AMP (cAMP)-dependent phosphorylation [7]. 
It is expressed in the apical membrane of the epithelial cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3 Scheme of CFTR gene, transcript, and mutation distribution. (A) Scaled schematic of exons 
and introns followed by current and historical exon numbering. (B) A rescaled exon scheme with 
minimized introns, which are drawn not to scale. (C) Distribution of known mutations and
polymorphisms as vertical bars [5]. 
 
Fig. 4 Structure of CFTR protein 
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3.1.2. Epidemiology of CFTR mutations 
Almost 2000 variants have been reported to the Cystic Fibrosis Mutation Database, one 
of the first locus-specific databases.  
The most common mutation is F508del, which accounts for approximately two thirds of 
all CFTR alleles in patients with CF, with a decreasing prevalence from Northwest to 
Southeast Europe. The remaining third of alleles is substantially heterogeneous, with 
fewer than 20 mutations occurring at a worldwide frequency of more than 0.1% (tab. 
1). In Europe, on average 1 in 2000-3000 newborns are affected with CF. Even where 
populations appear relatively homogeneous, there may be marked local and regional 
variations.  
CFTR gene mutations have been well characterized in most European populations. 
F508del frequencies vary from a maximum of 100% in the isolated Faroe Islands of 
Denmark, to a minimum of about 20% in Turkey. In central, northern, western, and 
north-eastern Europe, F508del has a frequency of about 70%. Apart from F508del, 5 to 
10 relatively frequent mutations contribute to 10%-15% of all CF-causing CFTR 
mutations, such as the G542X, N1303K, and G551D mutations. Ethnic specific mutations 
are observed in some populations such as the Nordic mutation 394delTT, the 3905insT 
mutation in Switzerland, the R1162X mutation in Northeast Italy, and the Eastern Slavic 
CFTR dele 2,3 (21kb) mutation. The remaining mutations are heterogeneous, private, or 
limited to a small number of individuals [8]. 
 
3.1.3. Type of CFTR mutations 
Among the reported 2000 variants, 40% are predicted to cause substitution of a single 
aminoacid, 36% are expected to alter RNA processing (including nonsense, frameshift 
and mis-splicing variants), about 3% involve large rearrangements of CFTR, and 1% 
affects promoter regions; 14% seem to be neutral variants, and the effect of the 
Tab.  1 Geographical distribution of the most common CFTR mutations [9]. 
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remaining 6% is unclear. Disease-causing variants can affect the quantity and/or 
function of CFTR at the cell membrane [3]. 
Historically, CFTR variants have been grouped into five functional classes.  
1. The I class comprise nonsense, frameshift and splice junction mutations, that 
lead to nonfunctional proteins, rapidly degraded. 
2. Mutations of II class are associated to defective processing and maturation of 
the CFTR protein, that is degraded before to reach plasmatic membrane. They 
are missense variants. This class includes the F508del. 
3. The III class comprises missense mutations that lead to defective regulation of 
the channel. They are located in the ATP binding domain or in site of 
phosphorylation into the R domain and cause suppression of CFTR function. 
4. Mutations of class IV are associated to defective conductance of the chloride. 
These are missense mutations that lead to functional CFTR protein, but with 
minor activity [10]. 
5. The V class includes splicing defects and missense mutations, leading to a 
reduced function and/or synthesis of CFTR channel (fig. 5).  
In general, patients homozygous for class I–III mutations exhibit a phenotype associated 
with pancreatic insufficiency, higher frequency of meconium ileus, premature mortality, 
earlier and more severe deterioration of lung function, higher incidence of malnutrition 
and severe liver disease. Class IV–V mutations are usually associated with milder lung 
disease, older age at death, pancreatic sufficiency. Class IV–V mutations are 
phenotypically dominant when occurring in combination with class I–III mutations [11]. 
 
 
  
Fig. 5 Molecular consequences of variants in CFTR. The degree to which epithelial ion transport is altered 
in an individual with cystic fibrosis is determined by the effect of each disease-causing variant on the 
quantity and the function of cystic fibrosis transmembrane conductance regulator (CFTR) [3]. 
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CFTR mutations can be clustered also according to their predicted clinical consequences 
[9]. They are divided into 4 groups: 
a. mutations that cause CF disease; 
b. mutations that results in a CFTR-related disorder; 
c. mutations with no known clinical consequences; 
d. mutations of unproven or uncertain clinical relevance. 
There is some overlapping of groups A and B, as some mutations may sometimes be 
detected in association with pancreatic sufficient CF, some other times with CFTR-
related, mono-symptomatic disorders (tab. 2). However, these relationships between 
certain classes of CFTR mutations and phenotypes are looser than expected and the 
phenotypic consequences of a significant number of CFTR gene changes remain unclear. 
Factors such as the age related progression of the disease, the environment, and 
modifier genes, all play a role in the clinical heterogeneity of patients carrying these 
“borderline” mutations [9]. 
 
3.1.4. Diagnosis 
The diagnosis of CF is suggested by one or more clinical signs and confirmed by an 
increased sweat chloride concentration. 
In 1998, a first consensus statement listing criteria for the diagnosis of CF was issued by 
the US Cystic Fibrosis Foundation [12].  
The fundamental criteria were: (i) one or more of the phenotypic features of the disease 
or (ii) a history of CF in a sibling or (iii) a positive immunoreactive trypsin (IRT, a neonatal 
screening test), in association with at least one other feature. The additional features 
Tab.  2 Examples of CFTR mutations with regard to their clinical consequences. 
(⁎) mutations which may belong either to Group A or to Group B. 
(⁎⁎) mutations which may belong either to Group B or to Group C. 
(⁎⁎⁎) certain common sequence (missense) variants with subclinical molecular consequences (e.g. 
M470V) may co-segregate on the same chromosome and exert more potent, cumulative phenotypic 
effect [9]. 
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included a positive sweat test result on two occasions, a CF-causing mutation in each 
CFTR gene or an abnormal nasal potential difference (NPD) [12]. 
In 2006 a European working group proposed a modified consensus statement, by 
focusing on different diagnosis of classic CF and atypical manifestation of CF. They 
suggested two diagnostic alghoritms, starting from different fundamental criteria 
exhibited by patients [13]. 
The CF diagnostic cascade start with the finding of one of these three situations: (1) 
clinical manifestations; (2) neonatal screening; and (3) family history. 
Clinical manifestation 
Many clinical problems are compatible with a diagnosis of CF, because this multiorgan 
disease is very heterogeneous and it has, at times, an atypical clinical presentation. 
The phenotypic features consistent with a diagnosis of CF are: 
1. Chronic sinopulmonary disease, manifested by persistent colonization/infection 
with typical CF pathogens, chronic cough and sputum production, persistent 
chest radiograph abnormalities, airway obstruction and nasal polyps. 
2. Gastrointestinal and nutritional abnormalities, including intestinal 
manifestations, pancreatic disease, hepatic symptoms. 
3. Salt loss syndromes. 
4. Male urogenital abnormalities resulting in obstructive azoospermia (CBAVD) 
[12]. 
Neonatal screening 
CF neonatal screening is based on the immunoreactive trypsinogen (IRT) assay, which is 
relatively inexpensive and adaptable to large numbers. Increased IRT concentrations at 
birth are characteristic of newborns affected by CF, but can also be found in healthy 
infants [13]. 
Family history 
It is strongly advised that siblings of affected children are investigated by a sweat test. 
Because of the remarkable clinical heterogeneity, even within families, lack of symptoms 
is insufficient to exclude the diagnosis of CF.  
 
The two different diagnostic CF algorithms proposed by Boeck et al. could be applied in 
the presence of one of the above mentioned three situations. In settings where the 
sweat test is available, the approach starting with this analysis is the preferred route. In 
patients with atypical disease manifestations the reliability of the sweat test is much 
lower and additional diagnostic tests will be necessary to substantiate the diagnosis. 
Thus, the algorithm starting with DNA analysis could be more appropriate. 
Sweat test 
The sweat test retains its position as a key diagnostic test for CF: the only acceptable 
procedure is the quantitative pilocarpine iontophoresis sweat test. 
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A sweat chloride concentration of more than 60 mmol/L is consistent with the diagnosis 
of CF, but the result must be interpreted in the context of the patient’s age and clinical 
picture by a physician knowledgeable about CF. On the other hand, levels below 40 
mmol/L are considered normal, but with a cautious interpretation in infancy and 
prematurity. The diagnosis of CF should be made only if the elevated sweat chloride 
concentration (>60 mmol/L) is revealed on two separate occasions [12]. 
CFTR mutation analysis 
The analysis for the identification of CFTR mutations could be divided into 3 categories: 
1. The analysis of first level identify specific or most common mutations, through 
technologies such as Reverse Dot Blot (RDB), Oligo Ligation Assay (OLA) or 
Amplification Refractory Mutation System (ARMS). Several commercial assays 
are available for CFTR mutation screening. Most tests only screen for about 30 
mutations, the majority of which are associated with classic CF. 
2. The second level analysis examine large portions of the gene to search every type 
of eventually present variants: they includes Denaturing HPLC (D-HPLC), 
Denaturing Gradient Gel Electrophoresis (DGGE) analysis, sequencing of the 
exons and intron-exon junctions of CFTR gene. They can be used in case of 
borderline sweat test and negative first level analysis. 
3. Finally, the third level analysis could identify rare rearrangements and intron 
variants not so close to exons and that cause splicing alterations. The 
technologies used are Multiplex Ligation-dependent Probe Amplification 
(MLPA), Quantitative Multiplex Polymerase chain reaction of Short Fluorescent 
fragments (QMPSF) and the study of nasal epithelia CFTR mRNA [14]. 
Only sequencing will approach 100% sensitivity. The other techniques, such as indirect 
mutation scanning assays, allow sensitivities varying from close to 100% to as low as 
90%. Even if a mutation is found, its involvement in disease may not be clear. For many 
CFTR mutations the functional consequences are unknown; they may even be 
polymorphisms [13]. 
Nasal potential difference 
Respiratory epithelia, including nasal epithelia, regulate the composition of fluids that 
wet airway surfaces by transport of ions such as sodium (Na+) and chloride (Cl–). This 
active transport of ions generates a transepithelial electrical PD, which can be measured 
in vivo. Abnormalities of ion transport in respiratory epithelia of patients with CF are 
associated with a different pattern of nasal PD compared with normal epithelia [12]. 
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3.1.5. Atypical CF 
There is great heterogeneity in the clinical manifestations of cystic fibrosis. Some 
patients may have all the classical manifestations of CF from infancy and have a 
relatively poor prognosis, while others have much milder or even atypical disease 
manifestations and still carry mutations on each of the CFTR genes. The CF phenotype is 
a continuum of symptoms and cannot be easily defined in two distinct disease categories 
(typical versus atypical CF). 
It has been demonstrated that, apart from their involvement in classical CF, CFTR 
mutations also cause, or contribute to, the CFTR-Related Disorders and so-called atypical 
CF. Patients with non-classic or atypical CF have a CF phenotype in at least one organ 
system and a normal (40 mmol/l) or borderline (40–60 mmol/l) sweat chloride level. 
Most of these patients has exocrine pancreatic sufficiency and milder lung disease [13]. 
A CFTR-related Disorder (CFTR-RD) is defined as a clinical entity associated with CFTR 
dysfunction that does not fulfill the diagnostic criteria for CF. Three main clinical entities 
illustrate these phenotypes: disseminated bronchiectasis, acute recurrent or chronic 
pancreatitis and congenital bilateral absence of the vas deferens (CBAVD) [15]. 
Disseminated bronchiectasis 
Bronchiectasis is a pathological description of lung damage characterized by an 
abnormal and irreversible dilatation of thick-walled bronchi. Affected areas are inflamed 
and easily collapsible, resulting in airflow obstruction and impaired clearance of 
secretions. Symptoms include recurrent lower respiratory tract infections, chronic 
cough and mucopurulent sputum production. In approximately 50% of cases, 
bronchiectasis is associated with underlying conditions such as CF, childhood infections, 
allergic broncho-pulmonary aspergillosis, immune defects, primary ciliary dyskinesia, 
aspiration of irritants, ulcerative colitis, rheumatoid arthritis and other connective tissue 
disorders. In the remainder of cases, causative factors cannot be identified [16]. An 
increased incidence of CFTR gene mutations has been found in bronchiectasis. At least 
one CFTR mutation was reported in 10–50% of a series of patients in different studies 
[17, 18]. Two mutations were found in 5–20% of cases, but not all studies specified 
whether a segregation analysis had been performed to establish if those subjects carried 
the two mutations in cis or in trans. Often, in these patients only one mutation is CF-
causing. No specific CFTR mutation is associated directly with bronchiectasis. Instead, a 
wide spectrum of CFTR mutations have been identified, most being uncommon and 
likely to result in residual CFTR function [18, 19]. The variety of CFTR mutations 
associated with bronchiectasis reflects the heterogeneous nature of this condition [15]. 
Idiopathic chronic pancreatitis (ICP) 
Chronic pancreatitis (CP) is a progressive inflammatory disease in which pancreatic 
secretory parenchyma is destroyed and replaced by fibrous tissue, eventually leading to 
impairment of the exocrine and endocrine functions of the organ [20]. 
About 10-30% of patients with chronic pancreatitis do not have an apparent underlying 
cause, and disease is classified as idiopathic pancreatitis [21]. 
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Genetic studies led to identification of a number of potential defects in genes, involved 
into pancreatic activities, which may contribute to the development of pancreatitis.  
In 1998 a research group reported an association between CFTR mutations and 
idiopathic chronic pancreatitis (ICP), by starting from three evidences: (i) both ICP and 
CF pancreatic disease show early ductal plugging resulting from inspissated secretions, 
(ii) CF patients occasionally suffer from pancreatitis and (iii) chronic pancreatitis is a 
known cause of false-sweat tests [22]. 
In the human exocrine pancreas, CFTR is predominantly expressed at the apical 
membrane of the ductal and centro acinar cells that line small pancreatic ducts, and 
controls cAMP-stimulated HCO−3 secretion into the duct lumen. The major role of CFTR 
in pancreatic ducts is to dilute and alkalinize the protein-rich acinar secretions, thereby 
preventing the formation of protein plugs that predispose to pancreatic injury [23]. 
About 30% of patients with ICP or recurrent acute pancreatitis are found to carry CFTR 
mutations. No specific CFTR mutations are associated with ICP, but rare or private class 
4 or class 5 mutations are generally found in these patients. CF-causing mutations, 
F508del being the most common, that generally have < 2% of normal CFTR function, 
lead typically to pancreatic insufficiency in homozygotes. In contrast, CF patients with 
genotypes producing about 5% of normal CFTR function often have pancreatic 
sufficiency [24].  
Recently, in a group of 33 patients with recurrent pancreatitis, Segal et al. [25] found 
that seven (21%) had an abnormal NPD even though their sweat chloride concentration 
and mutation profile did not differ from control subjects. 
CBAVD  
Congenital bilateral absence of the vas deferens (CBAVD) in otherwise healthy males 
accounts for approximately 3% of cases of infertility. The incidence of CBAVD, based on 
estimations, is approximately 1:1000 males [26]. While the prevalence of CF is very low 
in non-Caucasian countries, the prevalence of CBAVD does not seem to differ between 
populations.  
In the majority of cases, isolated CBAVD is recognized as an autosomal recessive genetic 
disorder associated with anomalies of the CFTR gene: alterations that retain enough 
residual CFTR function might result in milder phenotypes such as CBAVD. 
CBAVD is caused by mutations in the two copies of the CFTR gene in 70–90% of cases 
depending on ethnic/geographic populations [27]. Thereby, the distribution of CFTR 
mutations and genotypes in CBAVD differs substantially from classical CF. Among males 
with two identified CFTR mutations, CF patients have either two severe (88%) or one 
severe and one mild/variable CFTR mutations (12%), whereas CBAVD males have either 
a severe and a mild/variable (88%) or two mild/variable (12%) CFTR mutations [28]. The 
two most common compound heterozygous genotypes found in European males with 
CBAVD are F508del in trans with IVS8-5T (28%) and F508del in trans with R117H (6%). 
CFTR gene defects in CBAVD are essentially point mutations. However, in a very small 
number of cases large rearrangements (deletions or duplications) within the CFTR locus 
are identified [29]. 
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Several studies provide evidence for genetic heterogeneity in CBAVD: a proportion of 
extensively studied men with CBAVD, variable depending on country of origin (6–15% in 
Europe [29]), do not display any abnormalities in the CFTR gene.  
3.1.6. CFTR modifier genes  
In the vast majority of classical CF patients both copies of the CFTR gene are mutated. 
However, in a minority of CF patients a mutation cannot be identified on both CFTR 
genes, i.e., in 1 to 2% of the CF patients of Northern Europe and in up to 8 to 10% in CF 
patients of Southern Europe (www.who.int/genomics/publications/en). In an even 
higher proportion of patients with CBAVD, atypical CF, chronic pancreatitis, or 
disseminated bronchiectasis, a mutation cannot be identified on both CFTR genes [28, 
30]. 
There is substantial evidence that genes other than CFTR may cause CF or CF-like 
disease. Indeed, a German family was described with a CF patient without CFTR 
mutations, and with an unaffected healthy sister who inherited the same CFTR genes 
from her parents [31]. In two American families, each with two affected sibs, no 
mutations could be found on both CFTR genes, the affected sibs inherited different 
parental CFTR genes [32]. 
Extensive understanding of CF pathophysiology presents an opportunity to interrogate 
candidate genes as potential modifiers (fig. 6). In the lungs, loss of CFTR leads to 
inflammation, neutrophil recruitment, tissue damage and replacement with fibrotic 
connective tissue. At least 50 genes encoding proteins that participate in these cellular 
and tissue functions have been investigated as candidate modifiers [33]. 
Moreover, apart from the defective chloride secretion, it has been demonstrated that 
loss of functional CFTR leads to an increased sodium absorption in the airways of CF 
patients. Sodium transport is mediated through the amiloride sensitive epithelial 
sodium channel (ENaC) [34]. Thus, ENaC could be considered a good candidate as CFTR 
modifier gene. 
 
  
Fig. 6 The relative contribution of modifier genes, CFTR, and environment on phenotype [35]. 
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3.1.7. ENaC  
The ENaC proteins were identified by expression cloning in the early 1990s [36].  
The ENaC subunits belong to the degenerin/ENaC family of ion channels, which fulfills a 
key role in Na+ and water homeostasis. 
ENaC forms a heteromeric channel composed of three homologous subunits α, β and γ. 
Each subunit has two trans-membrane domains, a large extracellular loop and cytosolic 
N- and C-termini. There are multiple ENaC proteins expressed in various epithelia, with 
the prototypical ENaC thought to consist of at least 1α, 1β, and 1γ ENaC subunit 
interacting to form a channel (fig. 7). Of these, the α-ENaC subunit is required for a 
functional channel, while β-ENaC or γ-ENaC alone do not appear to form a conducting 
protein [36].  
The three subunits are encoded by three different genes: SCNN1A (sodium channel 
nonvoltage-gated 1, alpha, 12p13), SCNN1B (sodium channel nonvoltage-gated 1, beta, 
16p12.2-p12.1) and SCNN1G (sodium channel nonvoltage-gated 1, gamma, 16p12).  
ENaC proteins are found in the apical membrane of sodium-absorbing epithelial cells, 
e.g. in the respiratory tract, distal nephron, distal colon, sweat and salivary ducts. In 
these epithelia, ENaC is the rate-limiting step of sodium absorption [37, 38].  
 
Interaction between CFTR and ENaC 
At present, the molecular mechanisms of the regulatory relationship of the three 
subunits within ENaC, and between ENaC and CFTR, are incompletely understood and 
subject of considerable controversy. 
In 1995 Stutts et al found that MDCK cells and 3T3 fibroblasts, when co-transfected with 
CFTR and αβγ-ENaC, exhibited reduced amiloride sensitive Na+ current in a Cl− free 
solution as compared to cells expressing αβγ-ENaC in the absence of CFTR [34]. 
Following studies observed the inhibitory effects of CFTR on ENaCs also in other cells 
[39, 40].  
Although there is a general agreement that understanding of the CFTR–ENaC interaction 
can clarify the pathophysiology of CF, the exact mechanism of their relationship is not 
clear. A number of possible mechanisms have proposed, such as regulation by chloride 
Fig. 7 Schematic representation of ENaC structure. 
 
23 
 
concentration [41], indirect effect through intermediary proteins [42, 43, 44] or direct 
protein–protein interaction between the two molecules [45]. 
Despite the poor knowledge about mechanism of interaction between CFTR and ENaC, 
it is generally accepted that the coordinated regulation and activity of CFTR and ENaC 
determine the composition of the airway surface liquid (ASL) in the lungs (fig. 8). CFTR-
mediated Cl– secretion enhances ASL volume while ENaC mediated Na+ absorption 
reduces it. Thus, an appropriate balance between CFTR and ENaC activity is essential for 
maintaining an optimal ASL volume; if not, disease will occur [46, 47]. 
In classical CF patients with loss-of-function mutations in both copies of the CFTR gene, 
the ASL depletion is explained by the lack of CFTR-mediated Cl– secretion and 
accelerated Na+ absorption. Interestingly, transgenic mice that overexpress SCNN1B in 
the lower airways have increased airway epithelial sodium absorption and present CF-
like lung disease symptoms [48, 49]. 
 
ENaC mutations and other diseases 
Mutations in ENaC are also known to be involved in two different human genetic 
diseases. Either too low or too high amounts of ENaC will thus cause disease. Activation 
of ENaC by mutations in either SCNN1B or SCNN1G causes Liddle’s syndrome, an 
inherited form of salt-sensitive arterial hypertension with enhanced renal sodium 
retention [51]. These dominant gain of function mutations lead to an enhanced channel 
activity by increasing the number of ENaC channels expressed at the cell surface and by 
increasing the channel’s open probability [52, 53]. Loss of function mutations in 
SCNN1A, SCNN1B, or SCNN1G cause autosomal recessive pseudohypoaldosteronism 
type I, characterized by severe renal salt-wasting and arterial hypotension [54]. 
Moreover, in PHA-I patients, the reduced reabsorptive capacity of the lungs leads to an 
increased ASL volume, which often results in recurrent respiratory problems [55]. 
Indeed, PHA-I patients were found with chronic lung disease that resembles that of CF 
in the absence of common CFTR mutations [56, 57]. 
Fig. 8 Na+ hyperabsorption leads to increased O2 consumption and airway surface liquid (ASL) volume 
depletion. A and B, schematic diagrams of Na+ absorption in normal and cystic fibrosis airway epithelia, 
respectively. Na+ is transported down its electrochemical gradient through ENaC in the apical membrane 
and is pumped out across the basolateral membrane by the Na+/K+-ATPase. Because airway epithelia are 
highly water permeable and have NaCl-permeable paracellular pathways, Cl− and H2O follow Na+ [50]. 
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ENaC mutations and atypical CF 
Given the observation that sodium hyperabsorption through ENaC is part of the basic CF 
pathology, and that mice that overexpress SCNN1B present CF-like disease, mutations 
in the genes encoding ENaC may potentially explain disease in patients with CF-like 
disease in whom a mutation cannot be identified on both CFTR genes.  
Two different groups have analyzed patients with atypical CF and with one or none CFTR 
mutations, to find causative ENaC mutations [58, 59]. 
In 2005 Sheridan et al. have analyzed 20 non-classic CF patients without CFTR mutations, 
showing respiratory manifestations. They sequenced the exons and the flanking introns 
of the genes encoding the α, β and γ-subunits of ENaC and they identified six novel 
sequence changes. Five were predicted to cause amino acid changes: R181W in SCNN1A 
and S82C, P267L, G294S and E539K in SCNN1B, whereas the sixth changed the highly 
conserved penultimate A in the 3’ splice site of SCNN1B intron 12 (1670–2 A to G). P267L, 
G294S and E539K variants were not found in ethnically matched control alleles; the 
three aminoacids mutated in patients were completely conserved in ENaC orthologues 
and paralogues in human, rabbit, mouse and rat. 
RT–PCR analysis of nasal epithelial RNA revealed that the 1670–2 A to G mutation 
resulted in two stable SCNN1B transcripts. The first retains 83 nucleotides from the 3’ 
end of intron 12 and is predicted to alter the amino acid sequence following codon 514 
and terminate after the addition of 188 novel residues. The second transcript lacks the 
first 33 nucleotides of SCNN1B exon 13 leading to a deletion of 11 amino acids that 
precede the second transmembrane domain (fig. 9). These results confirmed that    
1670-2 A to G causes aberrant splicing leading to mRNA transcripts with substantial 
alterations in sequence. 
 
 
They also investigated the effect of the three missense mutations on ENaC function, by 
using Xenopus laevis oocytes; they found that oocytes injected with E539K βENaC or 
Fig. 9 RT–PCR analysis of SCNN1B 1670–2 A to G.  
RT-PCR with primers placed in SCNN1B exons 12 and 13 to analyze the exon 12/exon 13 junction in 
transcripts was performed. RT–PCR products were sequenced. Two different mutant transcripts were 
present [58]. 
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P267L βENaC generated Na+ currents significantly lower than those of wild-type. In 
contrast, the co-expression of G294S βENaC produced Na+ currents that were 
significantly higher than those of wild-type. Thus, each of the found missense SCNN1B 
mutations was associated with abnormal function (fig. 10). 
Together, these data indicate that the SCNN1B mutations discovered in these patients 
were likely to be deleterious [58]. 
 
 
 
In 2009 Azad et al. have analyzed 76 patients with CF or CF-like lung symptoms, carrying 
one or none CFTR mutation and/or with a positive or borderline sweat test. They 
sequenced the exons and the flanking introns of the genes encoding α, β and γ-subunits 
of ENaC. They identified a total of 30 sequence variants, some of which were previously 
described by Sheridan (fig. 11). 
Among selected variants, only the hyperactive V114I and hypoactive F61L mutations in 
SCNN1A were observed once in their patients, but not in controls. They suggested that 
these mutations could potentially cause disease by a Mendelian mechanism. 
Interestingly, the hyperactive V114I-SCNN1A mutation was identified in the German 
patient that provided the first evidence that mutations in other genes than CFTR may 
cause CF-like disease [31]. 
The cumulative frequency of mutations that have a minor allele frequency of <2.5% in 
controls had a more than three-fold significantly increased cumulative frequency (30%) 
in the studied patient group. Among these, the most relevant functional variant   
W493R-SCNN1A was found at a more than two-fold significantly increased incidence in 
patients (8%). 
From a genetic point of view, all these observations suggested an involvement of ENaC 
in disease in some of these patients [59]. 
Fig. 10 Functional studies of SCNN1B mutants expressed in Xenopus oocytes. Histogram of normalized 
mean currents (+SEM) at a membrane potential of -100 mV for oocytes injected with RNA encoding wild-
type α- and γ-ENaC plus wild-type βENaC, n= 40 from nine batches; βENaC P267L, n= 14 from four batches; 
βENaC G294S, n= 27 from six batches; or βENaC E539K, n=12 from six batches. Asterisks indicate P-values 
less than 0.005 when compared with wild-type [58]. 
 
 
26 
 
 
 
  
Fig. 11 Schematic diagram of the different SCNN1A, SCNN1B, and SCNN1G mutations found in the study 
of Azad et al. The coding exons and their flanking 30 nucleotides in the introns were analyzed. Translation 
initiation and termination are shown by arrows. Open boxes refer to the untranslated region (UTR), black 
boxes refer to coding exon, and gray boxes refer to protein [59]. 
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3.2. MATERIALS AND METHODS 
3.2.1. Design of ENac typing test prototype 
A prototype for identification of ENaC variants, probable involved in pathogenesis of 
atypical cystic fibrosis (GENEQUALITY ENaC-TYPE), was planned. After an in silico study 
for primers and probes selection, the prototype was manufactured.  
Our test allows detection of 9 ENaC variants through RLB technology. These mutations 
have been previously described, first by Sheridan et al. [58] and then by Azad et al. [59]. 
They demonstrated a correlation between these functional variants and atypical 
respiratory phenotypes. Mutations frequencies were significantly higher in patients 
rather than in controls. 
Variants, their genomic position, their effect on protein and frequency in the general 
population are summarized in tab. 5. 
3.2.2. PCR design 
Design of primers 
Design and analysis of primers can be divided into three phases: 
1. Selection of the target region. 
2. Design of primer pairs. 
3. Analysis of primers. 
The genomic target sequence was identified using GenBank and dbSNP. These are open 
access databases of the NCBI (National Center for Biotechnology Information) 
containing a collection of publicly available nucleic acid and protein sequences and their 
genetic variations within and across different species. 
The UCSC Genome Browser is a web-based graphical viewer that allows locating DNA 
sequences in the whole genome. It provides a fast display of any requested portion of 
the genome at any scale, together with annotation tracks (known genes, predicted 
genes, ESTs, mRNAs, CpG islands, assembly gaps and coverage, chromosomal bands, 
mouse homologies, and more) to recognize other possibly relevant features present in 
such a region.   
NCBI genomic sequences used are summarized in tab. 3. 
Primers have been designed by using 2 bioinformatics tools: Primer Express® Software 
v3.0.1  (Life Technologies) and DNA Mate (http://melolab.org/dnaMATE/tm-pred.html). 
Primer Express® is a tool licensed from Life Technologies, that allows to design primers 
and probes using TaqMan® and SYBR® Green I dye chemistries for gene quantitation and 
allelic discrimination (SNP) real-time PCR applications. It is possible to project primers 
starting form an input sequence given by the operator or to draw manually 
oligonucleotides. Finally, for each primer, it gives information about temperature of 
melting, content of GC, amplicon length, probability of secondary structures formation. 
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DNA Mate is a program that calculates the annealing or melting temperature of any 
given short DNA sequence (in the range of 16-30 nt) using five different approximations. 
A merged or consensus temperature among all calculations is also given. In addition to 
this, the server will inform to the user about the expected variation of the melting 
temperature estimation, which depends on the specific oligonucleotide sequence.  
All the selected primers satisfy some common features:  
- primer length: 18-25bp 
- amplicon length: 100-300bp 
- no dinucleotide repeats or long stretches of guanosine (G) 
- less than 3bp difference in length between primer pairs 
- melting temperatures (Tm) between 60°C and 65°C 
- GC content between 40% and 60% 
- balanced distribution of GC-rich and AT-rich domains 
- no intra-primer homology (more than 3 bases that complement within the 
primer) or inter-primer homology (forward and reverse primers having 
complementary sequences) to avoid self-dimers or primer-dimer formation. 
After designing primers, a BLAST search was performed to determine their specificity 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). The goal is to avoid no specific alignment with 
other regions different from the target sequence, not only in the human genome, but 
also for other microorganisms. 
Sequences of primers are not reported, in protection of trade secret. 
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Tab. 3. Description of ENaC variants detected with our test.   * chromosomic localization of variants, as reported in UCSC (Human Genome Browser).  ** frequency of each variant, 
reported in the 1000 Genomes database, for European population
SNP GENE ALTERNATE NAMES 
REFERENCE SEQUENCE 
(RefSeq-GeneBank ID) 
GENOMIC POSITION*  
GENIC 
FUNCTION 
FREQUENCY ** AMPLIFIED 
PRODUCT 
rs61758859 SCNN1A 
c. C183A 
p. F61L 
NT_009759.15 
NM_001038.4 
chr12: 6,483,717-6,483,817 
band:12p13.31 
exon 2 
Loss of function 
mutation 
 
N.A. 
 
290 bp 
rs61759861 SCNN1A 
c. C340T 
p. V114I 
NT_009759.15 
NM_001038.4 
chr12: 6,483,560-6,483,660 
band: 12p13.31 
exon 2 
Gain of function 
mutation 
 
MAF < 0.01 (T) 
 
290 bp 
rs61759925 SCNN1A 
c.G541A 
p.R181W 
 
NT_009759.15 
NM_001038.4 
chr12: 6,472,702-6,472,802 
band: 12p13.31 
exon 3 
Gain of function 
polymorphism 
 
MAF=0.02 (A) 
 
70 bp 
rs5742912 SCNN1A 
c.A1477G 
p.W493R 
NT_009759.15 
NM_001038.4 
chr12: 6,458,300-6,458,400 
band: 12p13.31 
exon 10 
Gain of function 
polymorphism 
 
MAF=0.02 (G) 
 
150 bp 
rs35731153 SCNN1B 
c.C245G 
p.S82C 
NT_010393.15 
NM_000336.2 
chr16: 23,360,115-23,360,215 
band: 16p12.2 
exon 2 
Loss of function 
mutation 
 
MAF < 0.01 (G) 
 
200 bp 
rs137852709 SCNN1B 
c.C799T 
p.P267L 
NT_010393.15 
NM_000336.2 
chr16: 23,379,150-23,379,250 
band: 16p12.2 
exon 5 
Loss of function 
mutation 
 
N.A. 
 
300 bp 
rs72654338 SCNN1B 
c.G880A 
p.G294S 
NT_010393.15 
NM_000336.2 
chr16: 23,379,230-23,379,330 
band: 16p12.2 
exon 5 
Gain of function 
mutation 
 
MAF < 0.01 (A) 
 
300 bp 
No registered SCNN1B p.1670-2A>G 
NT_010393.15 
NM_000336.2 
chr16: 23,391,764-23,391,739 
band: 16p12.2 
Intron 12 
Loss of function 
mutation 
 
N.A. 
 
260 bp 
rs137852710 SCNN1B 
c.G1615A 
p.E539K 
NT_010393.15 
NM_000336.2 
chr16: 23,391,764-23,391,864 
band: 16p12.2 
exon 12 
Loss of function 
mutation 
 
N.A. 
 
260 bp 
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Design of PCR reaction 
The polymerase chain reaction (PCR) is a technology that allow the specific and 
exponential amplification of a specific sequence of DNA.  
The method relies on thermal cycling, consisting of cycles of repeated heating and 
cooling of the reaction for DNA melting and enzymatic replication of the DNA.  
Specificity is given by primers, which are complementary to the target region; they also 
be necessary for the initiation of DNA synthesis by DNA polymerase. This enzyme 
enzymatically assembles a new DNA strand from the nucleotides, by using single-
stranded DNA as a template.  
The reaction of PCR is composed by three phases: denaturation, annealing and 
extension, which are repeated for a number of times variable between 25 and 50. 
For our amplification protocol, a particular Hot Start Taq Polymerase has been used; it 
is a recombinant enzyme, given in inactive state through link with antibodies, and  
requires a thermal activation. This enzyme avoid no specific amplifications during phases 
of reagents preparation, which could be performed at room temperature. 
A specific reaction buffer, provided with Taq polymerase and containing the denaturing 
agent DMSO, has been used in order to raise efficiency of amplification for some 
sequences with a high percentage of guanine and cytosine. 
The amplification protocol has been designed as a multiplex PCR; all the investigated 
ENaC variants are amplified in a unique reaction. 
Commercial names of reaction Mix and Taq polymerase, qualitative and quantitative 
composition of oligomix are omitted, in protection of trade secret. 
In the following table the thermal profiling of PCR is reported. 
 
Hold Temperature Time Number of 
cycles 
Hot start 95°C  5 minutes 1 
Denaturation 95°C  30 seconds 
40 Annealing 58°C  90 seconds 
Extension 72°C  30 seconds 
Final Extension 68°C  10 minutes 1 
Storage 10°C  ∞ 1 
 
Tab. 4. Thermal cycling used for the multiplex amplification of ENaC variants. 
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3.2.3. RLB design 
Design of probes 
For each investigated ENaC variant two probes have been designed: one specific for the 
wild-type sequence and one for the allelic variant. In total 18 probes have been 
designed. Genotyping probes have been elaborated on the same genes RefSeq, used for 
the primers. 
3 bioinformatics tools have been used:  
1. DNA Mate (http://melolab.org/dnaMATE/tm-pred.html), for the evaluation of 
melting temperature. 
2. DNA Folding Form application (http://mfold.rna.albany.edu/?q=mfold), to 
analyze the amplicon folding and to evaluate the presence of possible secondary 
structures that can prevent annealing with probe. 
3. Two state melting application (http://mfold.rna.albany.edu/?q=DINAMelt), to 
evaluate temperature of hybridization between probe and target sequence. 
All the selected probes satisfy some common features:  
- central position, in the sequence, of mismatch that differentiate wild-type from 
variant; 
- average length of 20 base pairs; 
- designed in regions not involved in strong secondary structures; 
- 53°C as temperature of hybridization with specific sequences; 
- ΔT of almost 4°C between temperatures of hybridization of the probes that 
identify the two allelic variants; 
- average temperature of melting between 65° and 70°C. 
Sequences of probes are not reported, in protection of trade secret. 
Strip manufacturing 
The support of the strip is a nitrocellulose baked membrane. The probes are spotted on 
nitrocellulose through an automatic work-station and then are immobilized on support 
by exposure to UV light, which induces the covalent bounds between oligos and 
membrane. 
Then, spotted membrane is incubated with a blocking solution containing BSA, for 30 
minutes in moderate shaking. This step prevents non-specific background binding of the 
DNA to membrane. 
Finally, membrane is cutted into single strips, through an automatic instrument. 
Each strip contains 18 genotyping probes: in the upper part of the strip there are probes 
relatives to variant alleles, while in the bottom part there are probes for wild-type 
alleles. Moreover, there is a staining control that guarantee the correct execution of 
post-hybridization steps and a reference line for the interpretation of resulting pattern 
(tab. 5 – fig. 12). 
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Probes concentration, buffer compositions, commercial name of nitrocellulose 
membrane and other details are omitted, for respecting intellectual proprietary and 
trade secret. 
Design of RLB protocol 
A RLB assay is influenced by several interconnected parameters. 
The stringency of the assay could be achieved by acting on two fundamental factors: 
temperature and ionic strenght of solutions. 
Temperature is a key on which it is possible to operate in order to achieve more 
stringency; a higher temperature makes less stable nonspecific duplex DNA-oligo and  
limits their formation. Temperature of the assay depends essentially by the optimal 
temperature of hybridization between DNA and probe. This is given by the structure of 
Position Description 
   Staining control 
  1 M. F61L 
  2 M. V144I 
  3 M. R181W 
  4 M. W493R 
  5 M. S82C 
  6 M. P267L 
  7 M. G294S 
  8 M. 1670-2A>G 
  9 M. E539K 
  10 W. F61L 
  11 W. V144I 
  12 W. R181W 
  13 W. W493R 
  14 W. S82C 
  15 W. P267L 
  16 W. G294 S 
  17 W. 1670-2A>G 
  18 W. E539K 
Staining control 
M. F61L                  1 
M. V114I                2 
M. R181W             3 
M. W493R             4 
M. S82C                 5 
M. P267L               6 
M. G294S              7 
M. 1670-2A>G     8 
M. E539K              9 
W. F61L               10 
W. V114I             11 
W. R181W          12 
W. W493R          13 
W. S82C              14 
W. P267L            15 
W. G294S           16 
W. 1670-2A>G  17 
W. E539K           18 
 
Tab. 5. Position of probes on strip. Probes M. type (pos. 1-9) identify variant alleles. Probes W. type (pos. 
10-18) identify wild-type alleles. 
 
Fig. 12 Example of probes pattern. Sample 1: individual omozygous wild-type for all analyzed variants.
Sample 2: individual omozygous for F61L mutation and wild-type for all the other variants. Sample 3: 
individual heterozygous for F61L mutation and omozygous wild-type for all the other variants. Sample 4: 
individual heterozygous for F61L mutation and R181W polymorphism and omozygous wild-type for all the 
other variants. 
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the probes: it is influenced by content of GC, length of oligos, number, position and types 
of mismatch between DNA target and oligos.  
The other factor that influences stringency of the assay is the ionic strength of the 
hybridization and washing solutions. A minor ionic strength results in a higher 
stringency. 
Finally, it is possible to act on incubation time of the several washing steps. 
Table 6 summarizes the RLB protocol of our test. 
 
Step Reagents Incubation 
Time of 
incubation 
1) Denaturation of amplicon 
Amplicon + Denaturation Solution, 
containing Sodium hydroxide 
Room temperature 5’ 
2) Hybridization 
Hybridization solution, containing 
Sodium citrate, Sodium chloride, Sodium 
dodecyl sulfate and preservatives 
52°C 
Moderate shaking 
30’ 
3) Stringent wash 
Stringent wash solution, containing 
Sodium citrate, Sodium chloride, Sodium 
dodecyl sulfate, and preservatives 
52°C 
Moderate shaking 
10’ 
5) Incubation with 
Streptavidine AP-Conjugated 
Streptavidine AP-Conjugated diluted in 
stringent wash solution 
52°C 
Moderate shaking 
30’ 
6) Wash 
Rinse solution, containing magnesium 
chloride, sodium chloride, Trizma and 
detergents. 
Room temperature 
Moderate shaking 
2’ 
7) Wash 
Rinse solution, containing magnesium 
chloride, sodium chloride, Trizma and 
detergents. 
Room temperature 
Moderate shaking 
2’ 
8) Colorimetric reaction 
NBT/BCIP solution, containing NBT, BCIP, 
Tris buffer and MgSO4 
Room temperature 
Moderate shaking 
AT DARK LIGHT 
10’ 
9) Blocking of reaction Blocking solution, containing Citric acid  
Room temperature 
Moderate shaking 
2’ 
10) Final wash Distilled water 
Room temperature 
Moderate shaking 
2’ 
 
Tab. 6. Scheme of visualization on strip protocol. 
3.2.4. DNA sequencing 
Samples resulting carrier of ENaC variants by RLB assay were sequenced to confirm the 
outcome. 
Amplicons have been purified by using ExoSap-IT® (Affymetrix), according to the 
manufacturer’s protocol. Reaction of sequencing was performed by BMR Genomics, 
with the BigDyes terminator cycle sequencing kit v3.1 (Applied Biosystems). The 
sequencing reactions were run on ABI 3730XL (Applied Biosystems) and ABI 3100 
(Applied Biosystems) and were analyzed with FinchTV software v1.4 (Geospiza).  
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3.2.5. Statistical analysis 
Differences in allelic frequencies between patients and controls were tested for each 
SNP with the use of a Fisher exact probability, because more than 25% of the cells had 
a count of <5. Genotypic odds ratios (ORs) and 95% confidence intervals (CIs) were 
estimated. 
3.2.6. Samples 
Clinical samples used in this study have been provided by different Italian institutes and 
analysis laboratories. Samples have been selected and afterwards they were made 
anonymous, randomized, classified and stored with a biobanking system. 
Genomic DNA was extracted from peripheral whole blood with the systems routinely 
used by the providing laboratory (tab. 7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tab. 7. Providing laboratory, matrix, extraction system and geographical information of the clinical 
samples. 
  
Number Laboratory of origin Matrix 
Extraction 
system 
Geographical 
informations 
226 
Laboratory of 
Molecular Pathology, 
Department of 
Pathology and 
Diagnostics, University 
Hospital of Verona 
Peripheral 
blood 
Qiamp DNA 
Blood Mini 
Kit (QIAGEN) 
Northern 
Italy 
7 
Laboratory of 
Molecular Pathology, 
Department of 
Pathology and 
Diagnostics, University 
Hospital of Verona 
Peripheral 
blood 
Qiamp DNA 
Blood Mini 
Kit (QIAGEN) 
Central 
Europe 
100 
Laboratory of 
Molecular Pathology, 
Department of 
Pathology and 
Diagnostics, University 
Hospital of Verona 
Peripheral 
blood 
BioRobot EZ1 
DSP system 
(QIAGEN) 
Northern 
Italy 
69 
Analysis Laboratory, 
Hospital of 
Bentivoglio, USL 
Bologna Nord 
Peripheral 
blood 
MagNA Pure 
Compact 
System 
(ROCHE) 
Northern 
Italy 
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In the following table, features of subjects, as phenotype and number of CFTR 
mutations, are summarized. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8. Number of subjects analyzed, divided on the basis of phenotype and number of CFTR 
mutations.*defined by second level analysis 
 
Phenotype 
CFTR mutation number Total of 
subjects 2 1 0* 
Number of 
subjects 
Respiratory 
manifestations 
58 9 27 94 
Chronic 
pancreatitis 
13 28 29 70 
Recurrent 
pancreatitis 
12 25 32 69 
Healthy - - 169 169 
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3.3. RESULTS AND DISCUSSION 
3.3.1. Optimization of ENaC typing test prototype 
In this Ph. D. project, we have developed a prototype for identification of ENaC variants, 
named GENEQUALITY ENaC-TYPE.  
Preliminary experimental tests have been made to set conditions of PCR and 
visualization on strip. We tested samples of known mutational status with different 
master mixes, different concentrations of primers and probes. The visualization of the 
PCR products by RLB was optimized testing different combinations of temperatures, 
washing solutions, and duration of incubation. Step by step, we compared the different 
conditions considering both intensity of signal on strip and absence of aspecific bands, 
to select a compromise between these features. 
3.3.2. Validation of ENaC typing test prototype 
After achieving the prototype standardization of our test, a phase of the project 
dedicated to the evaluation of the diagnostic performance was started. 
The performances of this assay have been evaluated on a total of 233 samples from 
affected patients and 169 from healthy individuals, as control group. 
The clinical criteria for patient recruitment were the presence of CF or CF-like lung or 
pancreatic symptoms, as well as of a positive or borderline sweat test and/or the 
presence of one CF-causing CFTR mutation. Only patients truly carrying one or no CF-
causing CFTR mutations were included. The absence of two CFTR mutations was 
confirmed by second level molecular analysis, such as sequencing of the complete CFTR 
coding region and its exon/intron junctions, or mutation scanning of the complete CFTR 
coding region and its exon/intron junctions using DGGE or dHPLC. The sensitivity of 
these scanning assays may not reach 100%, so a CFTR mutation might have escaped 
detection.  
Patients have been divided into 2 groups on the bases of their phenotype: 94 individuals 
with respiratory symptoms and 139 patients with pancreatic manifestations. 
Healthy control group 
The prevalence of ENaC variants was first determined in the group of 169 healthy 
individuals. 
In this group, 17 individuals carried an ENaC variant, mainly the polymorphism p.W493R-
SCNN1A. A smaller part showed the mutation p.S82C-SCNN1B or the polymorphism 
p.R181W-SCNN1A. 
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In the following table there is summarized the identified ENaC variants for the 17 
individuals. 
 
N. of individuals SCNN1A VARIANT SCNN1B VARIANT 
10 W493R - 
3 R181W - 
4 - S82C 
 
Tab. 9. Distribution of ENaC variants in the group of healthy controls. 
 
Patients with respiratory manifestations 
Patients with CF-like lungs symptoms were divided into 3 groups based on the number 
of CFTR mutations: 
A. 9 individuals with atypical CF, heterozygous for CFTR mutation  
B. 27 patients with atypical CF, without any CFTR mutation 
C. 58 patients with classic CF, homozygous or compound heterozygous for CFTR 
mutations 
In the group A, 7 ENaC variants have been identified: two polymorphisms p.R181W-
SCNN1A and p.W493R-SCNN1A and five mutations p.S82C-SCNN1B, p.P267L-SCNN1B, 
p.G294S-SCNN1B, p.E539K-SCNN1B and p.1670-2A>G-SCNN1B. Three patients carried a 
single ENaC variant, while five were compound heterozygous for ENaC mutations. One 
individual did not carry any ENaC variant. Patients n. 5 and n. 6 belonged from the same 
family; the same was for individuals n. 7 and n. 8. 
Table 10 summarizes the identified ENaC variants and CFTR mutation for each patient. 
 
PATIENT AH* SCNN1A VARIANT SCNN1B VARIANT CFTR MUTATION 
1  R181W - G542X 
2  W493R - ΔF508 
3  - S82C 3849+10 kbC>T 
4  W493R S82C R347P 
5 - 
P267L 
1670-2A>G 
ΔF508 
6 - 
P267L 
1670-2A>G 
ΔF508 
7  - 
G294S 
E539K 
ΔF508 
8  - 
G294S 
E539K 
ΔF508 
9  - - R1162X 
 
Tab. 10. Atypical heterozygous patients, with relative ENaC variants and CFTR mutation (group A). *AH= 
Atypical Heterozygous 
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In the group B, only three patients carried ENaC variants: one showed the polymorphism 
p.R181W-SCNN1A, and two the p.W493R-SCNN1A polymorphism, as summarized in 
table 11. 
 
PATIENT AN* SCNN1A VARIANT SCNN1B VARIANT 
1  R181W - 
2  W493R - 
3  W493R - 
 
Tab. 11. Atypical patients without CFTR mutations and their ENaC variants (group B). *AN= Atypical No 
CFTR mutation 
 
In the group C, only three individuals carried ENaC variants. Two of them showed the 
p.W493R-SCNN1A polymorphism, while the other carried the p.S82C-SCNN1B mutation, 
as summarized in table 12. 
 
PATIENT CCF* SCNN1A VARIANT SCNN1B VARIANT CFTR MUTATIONS 
1  - S82C ΔF508/3849+10 kbC>T 
2  W493R - ΔF508/ΔF508 
3  W493R - ΔI507/ΔI507 
 
Tab. 12. Classic CF patients with relative ENaC variants and CFTR mutations (group C). *CCF= Classic CF 
 
The prevalence and distribution of each ENaC variant in patients and control groups 
have been analyzed and relative allelic frequencies have been calculated (tab. 13). 
 
SNP REFERENCE VARIANTS 
OBSERVED ALLELIC FREQUENCY 
(mutated allele) EXPECTED 
ALLELIC 
FREQUENCY* 
ATYPICAL CF 
PATIENTS 
(n=36) 
CLASSIC CF 
PATIENTS 
(n=58) 
TRUE 
CONTROLS 
(n=169) 
rs61758859 C>A F61L - - - no data 
rs61759861 C>T V114I - - - 0 
rs61759925 G>A R181W 0.03 - 0.009 0.02 
rs5742912 A>G W493R 0.05 0.02 0.03 0.02 
rs35731153 C>G S82C 0.03 0.009 0.01 <0.01 
rs137852709 C>T P267L 0.03 - - no data 
rs72654338 G>A G294S 0.03 - - <0.01 
No registered A>G 1670-2A>G 0.03 - - no 
registered SNP rs137852710 G>A E539K 0.03 - - no data 
 
Tab. 13. Summary of the detected ENaC variants and their allelic frequencies. *Frequencies reported in 
the 1000 Genomes Database, for European population. 
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The allelic frequencies have been used to perform a statistical analysis, in order to 
evaluate possible significative differences between atypical affected and healthy 
controls. 
On the total of seven identified variants in this group of patients, only four had a 
frequency significantly higher in affected than in controls. These are the loss of function 
mutations p.E539K-SCNN1B, p.1670-2A>G-SCNN1B and p.P267L-SCNN1B and the gain 
of function mutation p.G294S-SCNN1B. They were found in two atypical patients (5.5%), 
at a more than five-fold increased incidence compared to controls (0%) (p-value=0.03), 
with an OR of 5.97 (95% CI, 4.39-8.11). 
The four significative mutations are located on SCNN1B gene. These results are partial 
in agreement with the findings that transgenic mice, overexpressing SCNN1B in the 
lower airways, have increased airway epithelial sodium absorption and present CF-like 
lung disease symptoms. It is possible that the amount of different ENaC subunits that is 
present in the cell is likely not equal. Indeed, the amount of a given subunit depends on 
many factors at the transcriptional and translational level. One subunit will thus be the 
limiting factor for the generation of functional ENaC channels. SCNN1B might be the 
limiting factor in the formation of functional ENaC channels, such that overexpression 
results in more ENaC activity and disease in transgenic mice [48].  
The polymorphism p.R181W-SCNN1A and the loss of function mutation p.S82C-SCNN1B 
were found in two affected individuals (5.5%), a three-fold increased incidence respect 
to control group of healthy individuals (1.7%), but the statistical analysis revealed that 
this difference was not significant (p-value=0.21). 
The remaining polymorphism p.W493R-SCNN1A was identified in four patients (11.1%) 
and in ten healthy individuals (5.6%); also in this case the difference was not significantly 
different between the two groups (p-value=0.27). 
The only difference between frequencies observed in our group of control and those 
reported in database was identified for p.R181W-SCNN1B polymorphism. This finding 
could be related to different geographical belonging of individuals. Our control group 
was entirely composed by Italian individuals, while frequencies reported by 1000 
Genomes Database were calculated on individuals from different European countries. 
Despite this difference, p.R181W-SCNN1B frequency in our group of atypicals was 
similar to value reported by database, although patients carrying the polymorphism 
were Italian. 
The four significative variants, identified in this study, were found in patients 
heterozygous for CFTR. They carried ΔF508 mutation, the most common causative 
variant of CF. When a disease-causing mutation is found on both CFTR genes, CFTR  
network is almost completely nonfunctional. However, in patients in whom a mutation 
is only found on one CFTR gene, about 50% of the network is still functional. This part of 
CFTR network may be rendered nonfunctional by a mutation in at least one other 
member of the CFTR network, such as ENaC. In these cases, ΔF508 account for damage 
of CFTR network and, probably, p.E539K-SCNN1B, p.1670-2A>G-SCNN1B, p.P267L-
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SCNN1B, p.G294S-SCNN1B affect functionality of remaining 50%. Thus, it is possible that 
ENaC mutation, in combination with a loss-of function mutation in one copy of the CFTR 
gene, may cause or predispose to CF or CF-like disease. 
However it is very difficult to develop an explanation of the effect of the different 
mutations, especially in the light that either too low or too high amounts of ENaC can 
already result in two different diseases, which will be even further complicated if the 
CFTR protein is implicated. 
Other ENaC variants were also detected in patients with explained CF and in healthy 
individuals, but their effect was null. In CF affects, disease is essentially given by the two 
CFTR disease-causing mutations, as expected. Therefore, it is possible to speculate that 
no disease will occur when these mutations are found alone in a heterozygous state.  
Patients with pancreatic manifestations 
Patients with CF-like pancreatic symptoms (chronic or recurrent) were divided in 3 
groups based on the number of CFTR mutations: 
A. 53 individuals with atypical CF, heterozygous for CFTR mutation 
B. 61 patients with atypical CF, without any CFTR mutation 
C. 25 patients with classic CF, homozygous or compound heterozygous for CFTR 
mutations 
In the group A, we have identified four individuals carrying ENaC variants. In particular, 
two of them showed chronic pancreatitis, while the other two had a clinical picture of 
recurrent pancreatitis. They carried the polymorphisms p.R181W-SCNN1A and 
p.W493R-SCNN1A and the mutation p.S82C-SCNN1B. Patients were heterozygous for CF 
causing mutations, as summarized in the table 14. 
 
PATIENT 
AH* 
PHENOTYPE 
SCNN1A 
VARIANT 
SCNN1B 
VARIANT 
CFTR MUTATION 
1  Recurrent pancreatitis R181W - W1282X 
2  Recurrent pancreatitis W493R - P5L 
3  Chronic pancreatitis R181W - ΔF508 
4  Chronic pancreatitis - S82C ΔF508 
 
Tab. 14. Atypical heterozygous patients with pancreatic symptoms, relative ENaC variants and CFTR 
mutations (group A). *AH= Atypical Heterozygous 
 
In the group B, only five patients carried ENaC variants: four of them showed the 
p.W493R-SCNN1A polymorphism, while one the p.R181W-SCNN1A. 
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Table 15 summarizes the identified ENaC variants for the five patients. 
 
PATIENT AN* PHENOTYPE SCNN1A VARIANT SCNN1B VARIANT 
1  Recurrent pancreatitis R181W - 
2  Recurrent pancreatitis W493R - 
3  Chronic pancreatitis W493R - 
4  Chronic pancreatitis W493R - 
5  Chronic pancreatitis W493R - 
 
Tab. 15. Atypical patients with pancreatic manifestations and no CFTR mutations and their ENaC variants 
(group B). *AN= Atypical No CFTR mutation 
The prevalence of the ENaC variants was also determined in the group C (tab. 16). 
In this group, only two individuals carried ENaC variants: one was a compound 
heterozygous for p.R181W-SCNN1A and p.S82C-SCNN1B, while the other carried the 
p.S82C-SCNN1B mutation. Interestingly, these two patients exhibited chronic 
pancreatitis, while individuals with recurrent pancreatitis did not carry any ENaC 
variants. 
 
PATIENT CCF* PHENOTYPE SCNN1A VARIANT SCNN1B VARIANT 
CFTR 
MUTATIONS 
1  Chronic pancreatitis R181W S82C ΔF508/(TG)12T5 
2  Chronic pancreatitis - S82C ΔF508/D1152H 
 
Tab. 16. Classic CF patients with relative ENaC variants and CFTR mutations (group C). *CCF= Classic CF 
patients 
 
In addition, the prevalence and distribution of each ENaC variant, in the group of 
patients with pancreatic manifestations, have been analyzed and relative allelic 
frequencies have been calculated (tab. 17).  
 
SNP REFERENCE VARIANTS 
OBSERVED ALLELIC FREQUENCY 
(mutated allele) 
EXPECTED ALLELIC 
FREQUENCY* 
ATYPICAL CF 
PATIENTS 
(n=114) 
CLASSIC CF 
PATIENTS 
(n=25) 
TRUE 
CONTROLS 
(n=169) 
rs61758859 C>A F61L - - - no data 
rs61759861 C>T V114I - - - 0 
rs61759925 G>A R181W 0.01 0.01 0.009 0.02 
rs5742912 A>G W493R 0.02 - 0.03 0.02 
rs35731153 C>G S82C 0.004 0.009 0.01 <0.01 
rs137852709 C>T P267L - - - no data 
rs72654338 G>A G294S - - - <0.01 
No registered A>G 1670-2A>G - - - no registered SNP 
rs137852710 G>A E539K - - - no data 
 
Tab. 17. Summary of the detected mutations and their allelic frequencies. *Frequencies reported in the 
1000 Genomes Database, for European population. 
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Statistical analysis, performed on allelic frequencies calculated above, has underlined 
the absence of any significative differences between atypical affected and healthy 
controls. 
The two polymorphisms p.R181W-SCNN1A, p.W493R-SCNN1A and loss of function 
mutation p.S82C-SCNN1B were identified both in the group of patients and in the 
controls, without any statistical difference between them.  
The polymorphism p.R181W-SCNN1A was found in three affected individuals (2.6%) and 
in three healthy individuals (1.7%); the difference was not clearly statistical significant 
(p-value=0.39). The second polymorphism p.W493R-SCNN1A was identified in five 
atypicals (4.4%) and in ten controls (5.6%) (p-value=0.78); finally p.S82C-SCNN1B 
mutation was found in only one affected (0.87%) and in the control group with the value 
of 1.7% (p-value=0.65). 
Interestingly, ENaC variants that appeared significative in the group of patients with 
respiratory symptoms (e.g. p.P267L-SCNN1B, p.G294S-SCNN1B, p.E539K-SCNN1B and 
p.1670-2A>G-SCNN1B), have not been identified in individuals with pancreatic 
manifestations.  
Frequency of identified ENaC variants were not significantly different between patients 
with recurrent pancreatitis and individuals with chronic pancreatitis. Among the 
patients with explained CF, only individuals with chronic pancreatitis carried ENaC 
variants. This finding has no statistical significance, because ENaC variants were 
detected in affected with recurrent pancreatitis, carrying one or none CFTR mutations. 
Therefore, the observed situation could be due to the low number of individuals in the 
group. 
All the variants identified by RLB assay were confirmed through sequencing (data not 
shown).  
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4. PART II: HCV GENOTYPING 
4.1. INTRODUCTION 
Hepatitis C virus (HCV) has been cloned in the 1989 [60, 61], and it is the principal cause 
of the so-called post-transfusion non-A, non-B hepatitis. 
HCV is a single-strand RNA virus, member of Flaviviridae family, Hepacivirus genus, 
although it is different in many details of its genome organization from the original 
members of the family. HCV is additionally distinct and somewhat unusual for an RNA 
virus in being able to establish persistent infections in the majority of exposed 
individuals. This phenomenon has attracted the greatest interest in HCV research, not 
least because long-term, chronic infections underlie its disease manifestations and 
effective therapy must break this ongoing cycle of replication in the liver [62]. 
4.1.1. Genetic variability of HCV 
Genetic variability of HCV exists at several different levels. Most obvious is the 
substantial genetic divergence of the main genotypes of HCV, which frequently show 
specific geographical ranges in the human population and associations with particular 
risk groups for infection. Below this, variability is observed between individual variants 
(or strains). It reflects processes of neutral sequence drift over time after the 
introduction of HCV into new risk groups in the 20th century. Some of the sequence 
divergence may represent phenotypically selected changes, associated with adaptation 
for replication in individuals with different immune responses. Finally, HCV diversifies  
within an infected individual overtime, forming what has been described as a 
quasispecies. This pre-existing genetic variability, combined with an extremely large 
replicating population size of HCV in a chronically infected individual, provides a large 
pool of genetic variants that can adapt to new selection pressures [62]. 
4.1.2. Genotypes 
Comparison of nucleotide sequences of variants, recovered from infected individuals in 
different risk groups for infection and from different geographical regions, has revealed 
the existence of at least seven major genetic groups. On average over the complete 
genome, these differ in 30–35% of nucleotide sites, with more variability concentrated 
in regions such as the E1 and E2 glycoproteins. Whereas sequences of the core gene and 
some of the non-structural protein genes, such as NS3, are more conserved. The lowest 
sequence variability between genotypes is found in the 5’ UTR, where specific sequences 
and RNA secondary structures are required for replication and translation functions. 
Within each genotype, HCV is further classified into 67 confirmed and 20 provisional 
subtypes (fig. 13) that typically differ from each other by 20–25% in nucleotide 
sequences [63].  
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Fig. 12 Phylogenetic tree of 129 representative complete coding region sequences. Up to two 
representatives of each confirmed genotype/subtype were aligned and a neighbor joining tree 
constructed using maximum composite likelihood nucleotide distances between coding regions using 
MEGA5.Sequences were chosen to illustrate the maximum diversity within a subtype. Tips are labeled by 
accession number and subtype (*unassigned subtype). For genotypes 1, 2, 3, 4, and 6, the lowest common 
branch shared by all subtypes and supported by 100% of bootstrap replicates (n= 1,000) is indicated by● 
[63]. 
 
Distribution of HCV genotypes 
The contemporary global geographic distribution of HCV genotypes is complex. It has 
already been established that a few subtypes—specifically 1a, 1b, 2a, and 3a—are 
widely distributed across the globe and account for a large proportion of HCV infections 
in high income countries. These so-called “epidemic subtypes” are thought to have 
spread rapidly in the decades prior to the discovery of HCV by way of infected blood, 
blood products, injecting drug use, and other routes [64, 65, 66].  
The model suggested by these genotype distributions is that HCV has been endemic in 
sub-Saharan Africa and South-East Asia for a considerable time, and that the occurrence 
of infection in Western and other non-tropical countries represents a relatively recent 
emergence of infection in new risk groups [67, 68]. In the 20th century, parenteral 
exposure to blood-borne viruses became frequent through the widespread adoption of 
blood transfusion since the 1940s, the medical use of often unsterilized needles for 
injections and vaccinations (a practice that continues in many developing countries) and, 
most specifically, to industrialized countries, injecting drug use and the sharing of 
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injection equipment. These new routes for transmission plausibly account for the 
epidemiological and genetic evidence for recent epidemic spread of HCV over the past 
50 years in Europe, Egypt and elsewhere [68, 69, 70]. 
Many other HCV subtypes are considered “endemic” strains; these are comparatively 
rare and have circulated for long periods in more restricted regions. Endemic strains 
from genotypes 1 and 2 are primarily in West Africa, 3 in south Asia, 4 in Central Africa 
and the Middle East, 5 in Southern Africa, and 6 in South East Asia (fig.14) [64, 67, 69]. 
To date, only one genotype 7 infection has been reported; it was isolated in Canada from 
a Central African immigrant [71]. 
The global distribution of HCV genetic variation has likely been influenced by historical 
and contemporary trends in human migration. For example, strains from West Africa 
appear to have been transferred to the America by way of the trans-Atlantic slave trade 
[72]. 
Globally, genotype 1 is estimated to account for more HCV cases than any other 
genotype at 83.4 million (46.2%), with over one-third of genotype 1 cases located in East 
Asia.  
HCV genotype 3 is the next most common and is estimated to account for 54.3 million 
(30.1%) cases globally, approximately three-quarters of which occur in south Asia; the 
remaining are located in parts of Scandinavia. 
Genotypes 2, 4, and 6 are responsible for the majority of the remaining cases of HCV 
worldwide, with an estimated 16.5 million (9.1%), 15.0 million (8.3%), and 9.8 million 
(5.4%) cases, respectively. East Asia accounts for the greatest numbers of genotype 2 
and genotype 6 HCV cases, while North Africa and the Middle East have the largest 
number of genotype 4 cases.  
Genotype 5 is responsible for the fewest HCV cases globally (1.4 million, <1% of all HCV 
cases), the great majority of which occur in Southern and Eastern sub-Saharan Africa. 
Genotype 6 is present at the highest frequencies in East and Southeast Asia, but is the 
dominant genotype in only one country, Laos; it is also prevalent in neighboring Vietnam 
[73]. 
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Fig. 14 Relative prevalence of each HCV genotype. Size of pie charts is proportional to the number of 
seroprevalent cases [74]. 
 
4.1.3. Viral structure  
HCV is an enveloped virus with a positive single-stranded RNA genome, of approximately 
9400 nucleotides in length. The genome contains a single ORF (Open Reading Frame), 
which is translated into polyprotein of 3000 aminoacids. This polyprotein is 
subsequently processed by viral and host proteases into 10 different proteins, three 
structural and seven nonstructural.  
The three structural proteins, which constitute the viral particle, include the core protein 
and the envelope glycoproteins E1 and E2. Two regions in E2, known as hypervariable 
regions 1 and 2, are reported to have extreme sequence variability. The seven 
nonstructural components include the p7 polypeptide, the NS2-3 protease, the NS3 
serine protease and RNA helicase, the NS4A polypeptide, the NA4B and NS5A proteins, 
and the NS5B RNA-dependent RNA polymerase. 
At both ends of the open reading frame lie the 5’- and 3’-untranslated regions (5’-UTR 
and 3’-UTR). The 5′-UTR is highly conserved among different HCV isolates and it is 
composed by four highly ordered domains numbered I to IV. Domains II and III constitute 
the IRES that is essential for cap-independent translation of the viral RNA. Domains I and 
II are both essential for HCV RNA replication [74]. The 3′-UTR is composed of a short 
variable region, a poly (U/UC) tract with an average length of 80 nucleotides, and an 
almost invariant 98 nucleotide RNA element, designated the X-tail. The conserved 
elements in the 3′-UTR, including a minimal poly (U) tract of about 25 bases, are essential 
for replication [75]. 
Besides the 5′- and 3′-UTRs, an essential cis-acting replication element (CRE) was 
identified in the sequence that encodes the C-terminal region of NS5B [76].  
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Virion structure 
Based on filtration and electron microscopic studies, HCV particles are 40–70 nm in 
diameter. It is thought that the core protein and the envelope glycoproteins E1 and E2 
are the principal protein components of the virion. E1 and E2 are presumably anchored 
to a host cell-derived double-layer lipid envelope that surrounds a nucleocapsid 
composed of multiple copies of the core protein and the genomic RNA (fig. 15). 
HCV circulates in various forms in the infected host. Virus can be associated with low-
density lipoproteins (LDL) and very-low-density lipoproteins (VLDL), both of which seem 
to represent the infectious fraction. It also circulates as free virions or bound to 
immunoglobulins [77].  
 
 
 
Structure and function of the viral proteins 
Core 
The first structural protein encoded by the HCV open reading frame is the core protein, 
which forms the viral nucleocapsid. An internal signal sequence located between the 
core and E1 sequences targets the nascent polypeptide to the endoplasmic reticulum 
(ER) membrane for translocation of the E1 ectodomain into the ER lumen. Cleavage of 
the signal sequence by signal peptidase yields an immature 191 aminoacids core protein. 
Further C-terminal processing yields the mature 21-kDa core protein of 173–179 
aminoacids. 
The N-terminal hydrophilic domain (D1) of the core protein contains a high proportion 
of basic aminoacid residues and has been implicated both in RNA binding and homo-
oligomerization. The core protein is a α-helical protein that is found on membranes of 
the ER and on the surface of lipid droplets. The association with lipid droplets, which is 
mediated by the central, relatively hydrophobic domain (D2), may have a role during 
viral replication and/or virion morphogenesis [78]. 
Fig. 15 Structure of HCV virion. 
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Envelope glycoproteins 
The envelope proteins E1 and E2 are glycosylated and form a non-covalent complex, 
which is the building block for the viral envelope. HCV glycoprotein maturation and 
folding is a complex process that involves the ER chaperone machinery and depends on 
disulphide bond formation as well as glycosylation. The transmembrane domains of E1 
and E2, located at their C-termini, are involved in heterodimerization and have ER 
retention properties. Each of them contains a hydrophobic patch that functions as an 
internal signal peptide for the downstream E2 and p7 proteins [79].  
p7 
p7 is a 63 aminoacid polypeptide that is often incompletely cleaved from E2. HCV p7 is 
not required for RNA replication in vitro but is essential for productive infection in vivo. 
It has been suggested to belong to the viroporin family, and that could have an 
important role in viral particle maturation and release [80]. 
NS2–3 protease  
The NS2–3 protease is also known as the autoprotease. As with all of the HCV proteins, 
NS2 is associated with intracellular membranes. It is dispensable for RNA replication in 
vitro but is essential for the complete replication cycle in vitro and in vivo, possibly by 
affecting a late step of the viral life cycle [81].  
NS3–4A complex 
NS3 is a multifunctional protein, with a serine protease located in the N-terminal one 
third and an RNA helicase/NTPase located in the C-terminal two thirds of the protein. 
The NS4A polypeptide functions as a cofactor for the NS3 serine protease. Its central 
portion is incorporated as an integral component into the enzyme core, and its N-
terminal portion is responsible for membrane association of the NS3–4A complex [82].  
NS4B 
NS4B is a relatively poorly characterized 27-kDa protein. One of its functions is to induce 
the formation of the membranous network, the specific membrane alteration that 
serves as a scaffold for the HCV replication complex [83]. 
NS5A  
NS5A is a phosphoprotein that can be found in basally phosphorylated (56 kDa) and 
hyperphosphorylated (58 kDa) forms. Phosphorylation of NS5A is a conserved feature 
among hepaciviruses and pestiviruses and is also found in flavivirus NS5 proteins. Thus, 
NS5A has an important role in the HCV lifecycle and probably modulates the efficiency 
of HCV RNA replication. NS5A would attach the viral RNA onto intracellular membranes 
and coordinate its different fates during HCV replication [84].  
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NS5B 
NS5B RNA-dependent RNA polymerase (RdRp) is the key enzyme responsible for HCV 
replication. First, a complementary negative-strand RNA is synthesized using the 
genome as a template and then, a genomic positive-strand RNA is synthesized from this 
negative-strand RNA template. This enzyme lacks of a proof-reading function; this 
feature, together with the high replicative activity, accounts for genetic variability of 
HCV. NS5b RdRp has been extensively characterized, and has emerged as a major target 
for antiviral intervention. [85]. 
ARFP/F proteins 
An alternative reading frame (ARF) was identified in the HCV core coding region, as a 
result of a –2/+1 ribosomal frameshift in genotype 1a. It has the potential to encode a 
protein of up to 160 amino acids, designated ARFP (alternative reading frame protein) 
or F (frameshift) protein. Amino-acid sequencing indicated that the frameshift probably 
occurs at, or near to, codon 11 of the core protein sequence [86]. 
However, the functions, if any, of the ARFP/F proteins in the life cycle and pathogenesis 
of HCV remain to be elucidated.  
 
 
 
 
  
Fig. 16 Genetic organization and polyprotein processing of hepatitis C virus (HCV). The 9.6-kb positive-
strand RNA genome is schematically depicted at the top. Simplified RNA secondary structures in the 5′- 
and 3′-UTR and the core gene are shown. Internal ribosome entry site (IRES)-mediated translation yields 
a polyprotein precursor that is processed into the mature structural and non-structural proteins. Amino-
acid numbers are shown above each protein (HCV H strain; genotype 1a; GenBank accession number 
AF009606). Solid diamonds denote cleavage sites of the HCV polyprotein precursor by the endoplasmic 
reticulum signal peptidase. The open diamond indicates further C-terminal processing of the core protein 
by signal peptide peptidase. Arrows indicate cleavages by the HCV NS2–3 and NS3–4A proteases. Dots in 
E1 and E2 indicate the glycosylation of the envelope proteins [75]. 
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4.1.4. Life cycle 
Viral entry 
HCV only infects humans and chimpanzees. Hepatocytes are the main target cells but 
infection of B cells, dendritic cells and other cell types has also been reported. CD81, a 
tetraspanin protein that is found on the surface of many cell types, including 
hepatocytes, the LDL receptor (LDLR), the scavenger receptor class B type I (SR-BI) and, 
most recently, claudin-1 (CLDN1) have, among others, been proposed as HCV receptors 
[87, 88, 89], but their role remains still not fully elucidated. CLDN1 functions at a late 
stage of cell entry, possibly at tight junctions of polarized hepatocytes. 
Virus internalization depends on clathrin-mediated endocytosis and the acidification of 
the endosome induces HCV glycoprotein membrane fusion. Little is known about the 
uncoating process, which results in genome release into the cytosol. 
Translations of viral proteins 
Domains II, III and IV of the 5′-UTR, together with the first 24–40 nucleotides of the core 
coding region, constitute the IRES. HCV translation initiation occurs through the 
formation of a binary complex between the IRES and the 40S ribosomal subunit. Then, 
a 48S-like complex is assembled at the AUG initiation codon, after the association of 
eukaryotic translation initiation factor3 (eIF3) and ternary complex (eIF2•Met-
tRNAi•GTP) [75]. 
Polyprotein processing   
Translation of the HCV open reading frame yields a polyprotein precursor that is co- and 
post-translationally processed by cellular and viral proteases into the mature structural 
and non-structural proteins. The structural proteins and the p7 polypeptide are 
processed by the ER signal peptidase whereas the non-structural proteins are processed 
by two viral proteases, the NS2–3 protease and the NS3–4A serine protease [75]. 
The viral replication complex 
The peculiar steps of HCV replication are the formation of a membrane-associated 
replication complex, the composition of viral proteins, replication of RNA and alteration 
of cellular membranes. Replication might occur on altered membranes derived from the 
ER, Golgi apparatus, mitochondria or even lysosomes. 
The role of membranes in viral RNA synthesis is not well understood. Several functions 
have been suggested: physical support and organization of the RNA replication complex, 
compartmentalization and local concentration of viral products, attachment of the viral 
RNA during unwinding, provision of lipid constituents important for replication and 
protection of the viral RNA from double-strand RNA-mediated host defenses or RNA 
interference [75]. 
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Recent studies have revealed a complex interaction between HCV RNA replication and 
cellular lipid metabolism, presumably through the trafficking and association of viral and 
host proteins with intracellular membranes [90].  
Packaging, assembly and particle release 
Little is known about the late steps of the viral lifecycle. NS2 and possibly other non-
structural proteins, as well as undefined RNA structures, are involved in these processes. 
Virions presumably form by budding into the ER, or an ER-derived compartment, and 
exit the cell through the secretory pathway [75]. 
 
 
4.1.5. Infections by HCV 
The World Health Organization (WHO) estimates that 170–200 million people 
worldwide, i.e., 3% of the world’s population, is infected with HCV. 
HCV prevalence is characterized by a high variability between world’s regions, individual 
countries and between age and risk groups. HCV prevalence is highest in Africa and the 
Middle East, where Egypt, Cameroon, Saudi Arabia, Iraq and Syria account for the 
majority of cases and prevalence ranges from 2% to 15%. North America, Australia, 
Japan and Northern and Western Europe report lower prevalence of HCV infection, with 
no country showing a rate > 2%. China, India, Egypt, Pakistan and Indonesia account for 
approximately half of the global HCV-infected subjects [91]. In general, developing 
countries present the major HCV-related burden but also the major limitations in 
surveillance: data from most African, Asian and South American countries are lacking.  
HCV prevalence in the majority of developed countries is classified as low, but marked 
differences in the epidemiological picture exist among countries, principally related to 
Fig. 17 Lifecycle of hepatitis C virus (HCV). Virus binding and internalization (a); cytoplasmic release and 
uncoating (b); IRES-mediated translation and polyprotein processing (c); RNA replication (d); packaging 
and assembly (e); virion maturation and release (f) [75]. 
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temporal and transmission factors and resulted in diverse age-specific distribution of 
HCV cases [92]. 
Natural history of HCV 
Acute HCV infection is mostly asymptomatic and rarely recognized clinically. 
In up to 45% of cases, acute HCV infection completely resolves, and this seems to be 
associated with a younger age at infection, female sex, and possibly certain major 
histocompatibility complex genes. However, about 55% to 86% of HCV infected patients 
develop chronic infection, manifested by the persistence of detectable HCV in the 
serum. This has been primarily attributed to the propensity of HCV to mutate and evade 
host defenses [93]. 
Chronic HCV is usually characterized by a lack of symptoms or only fatigue or vague 
abdominal pain. Extra hepatic manifestations of chronic HCV may be identified, and 
these are associated primarily with autoimmune or lymphoproliferative states. 
Increases in serum alanine aminotransferase (ALT) reflect hepatocyte injury, but these 
values typically fluctuate overtime and may be even normal on occasion. 
The major complication of chronic HCV infection is progressive hepatic fibrosis leading 
to cirrhosis, which develops in about 20% of patients with chronic HCV [94]. The natural 
history of chronic HCV is variable, and progression of chronic liver disease is insidious in 
most patients. About one third of patients with chronic HCV develop hepatic cirrhosis 
15 to 20 years after infection (‘‘rapid fibrotic progressors’’), one third develop cirrhosis 
20 to 30 years after infection (‘‘intermediate fibrotic progressors’’). The remaining one 
third develop it only after 30 years of HCV infection (‘‘slow fibrotic progressors’’) [95]. 
However, a number of factors can accelerate progression to advanced liver disease, such 
alcohol consumption, co-infection with HIV or hepatitis B virus, and older age at the time 
of infection. Obesity and hepatic steatosis are also emerging independent predictors of 
more severe liver fibrosis. 
Chronic HCV infection is associated with an increased risk of hepatocellular carcinoma, 
but this occurs primarily in patients with cirrhosis. Factors that increase the risk of 
hepatocellular carcinoma among HCV infected people include male sex, older age, 
chronic hepatitis B infection, and heavy alcohol ingestion (>50 grams/day). Once 
cirrhosis is established, the incidence of hepatocellular carcinoma is 1% to 4% per year. 
Death from chronic HCV typically occurs because of decompensated cirrhosis or 
hepatocellular carcinoma [94]. 
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4.1.6. Therapy 
The treatment available for HCV has changed significantly over recent decades, with the 
standard of care shifting from conventional interferon (IFN) monotherapy to IFN and 
ribavirin combination therapy to PEGylated IFN (PEG-IFN) with ribavirin. IFNα has potent 
antiviral activity due to its ability to induce IFN-stimulated genes that encode proteins, 
inhibiting various stages of viral replication. In addition, IFNα has an immunomodulatory 
effect, interacting with both the adaptive and innate immune response of the host. IFNα 
promotes T-helper (Th) cell differentiation of T-lymphocytes over Th2 cells, leading to 
increased production of interleukin (IL)-2 and IFNγ. Moreover, IFNα exerts an anti-
inflammatory effect by inhibiting the synthesis of various cytokines, including tumor 
necrosis factor-alpha and IL-1 [96].  
The mechanisms of action of ribavirin are not fully understood. It has been postulated 
that ribavirin acts via direct inhibition of HCV replication, inhibition of the host inosine 
monophosphate dehydrogenase enzyme, induction of mutagenesis to drive a rapidly 
Fig. 18 Natural history of HCV infection [94]. 
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replicating virus beyond the threshold to error catastrophe, and immunomodulation by 
inducing a Th1 immune response [97]. 
The primary goal of antiviral therapy in patients with chronic hepatitis C is achieving a 
Sustained Virological Response (SVR), defined as undetectable serum HCV-RNA by a 
sensitive molecular assay 24 weeks after completion of therapy. Although the standard 
of care improves SVR rates in HCV genotypes 2 and 3, the response is still suboptimal in 
genotypes 1 and 4 and in particular patient populations; therapy fails in 50%–60% of 
patients with HCV genotype 1 and approximately in 20% of those with HCV 2 and 3. 
Management of relapsers and nonresponders remains a challenging and controversial 
issue. In addition, all of the IFN-based regimens have moderate to severe side effects, 
including hematologic adverse events (neutropenia, thrombocytopenia), fatigue, 
irritability, fever, myalgia, arthralgia, inflammation at the injection site, and cardiac 
dysrhythmia, that negatively influence the tolerability and adherence of patients with 
therapy [98]. 
Moreover, a number of host and viral factors influence SVR rates in patients with chronic 
HCV. A SVR is more likely in young individuals, females, patients infected with genotypes 
2 or 3, and those with low pretreatment HCV-RNA levels, no or minimal liver fibrosis, 
and adequate adherence to therapy. Infection with HCV genotype 1 or 4, high baseline 
HCV RNA levels (>800,000 IU/mL), steatosis, insulin resistance, and co-infection with HIV 
are associated with low response rates [99]. 
Since genotype 1 is the most frequent genotype in chronically infected patients 
worldwide, the need for more efficacious therapies is becoming urgent. 
All of the above factors have driven a need to develop new treatments that are safer 
and more effective. Recently, a number of direct-acting antiviral agents (DAAs) have 
been developed for use with PEG-IFN/ribavirin as triple therapies or IFN-free therapy. 
The efficacy of such therapeutic regimens varies according to genotype and host 
characteristics.  
Direct-acting antiviral agents 
DAAs were developed to increase SVR rates, reduce adverse events, and improve 
adherence to therapy in HCV patients.  
Increased understanding of the HCV life cycle in recent years has supported the 
development of direct-acting antiviral (DAA) agents that specifically target post-
translational processing and HCV replication. 
The targets of currently approved or in development molecules are related with HCV 
replication, specifically translation and polyprotein processing (NS3/4A), HCV genome 
replication (NS5B polymerase and NS5A), and viral assembly (NS5A) [100]. 
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NS3/4A Inhibitors 
Inhibition of NS3 and its cofactor, NS4A, results in blocking proteolytic maturation of a 
large portion of the nonstructural region of the HCV polyprotein, NS3 to NS5B.  
A number of other protease inhibitors, which have been developed and in phase II or III 
clinical trials, are classified as “first-generation” and “second-generation” according to 
degree of genetic barrier to resistant HCV and genotype coverage. The first-generation 
protease inhibitors include boceprevir, telaprevir, simeprevir (TMC-435), faldaprevir 
(BI201335), vaniprevir (MK-7009), and asunaprevir (BMS-650032).  
The second-generation protease inhibitors, characterized by potent activity against pan-
genotypes and high genetic barrier to resistance, include MK-5172 and ACH-2684 in 
phase II clinical trial [102]. 
Boceprevir and telaprevir represents the first-wave of the first-generation oral protease 
inhibitors and they have been assessed in large clinical trials. These agents have been 
approved by regulatory authorities and are currently used in clinical practice. Boceprevir 
acts as a noncovalent inhibitor of cytochrome P450 A4 and P-glycoprotein. Addition of 
boceprevir or telaprevir to PEG-IFN and ribavirin significantly increased SVR rates and 
shortened the treatment duration in naïve, relapsing, and partially responding patients.  
Current practice guidelines recommend a triple therapy regimen combining PEG-IFN, 
ribavirin, and telaprevir or boceprevir. However, triple therapy has some drawbacks, 
including drug–drug interactions and viral resistance. This regimen increases adverse 
events such as rash and moderate to severe anemia to an extent that might require 
reduction of the ribavirin dose. Boceprevir and telaprevir are only effective against 
genotype 1, with recent studies showing that these protease inhibitors have no antiviral 
Fig. 19 Steps in the HCV life cycle targeted by DAAs (shown in cyan). Abbreviations: E, enevelope 
glycoprotein; NS, nonstructural protein; + and -, positive and negative HCV RNA strands. aNot approved 
by the US Food and Drug Administration [102]. 
 
56 
 
activity against genotype 2, 3, or 4. Further, triple therapy is ineffective in patients who 
have not responded to previous dual PEG-IFN/ribavirin therapy [98]. 
The second-wave of first-generation protease inhibitors comprises simeprevir, 
asunaprevir, and danoprevir, which are currently being evaluated in an effort to 
overcome the limited efficacy of the first-wave protease inhibitors in HCV genotypes 2, 
3, and 4 and to minimize their adverse events [98]. 
NS5A Inhibitors 
NS5A is a dimeric protein required for HCV RNA replication and virion assembly. NS5A 
inhibitors have potent antiviral activity, but the genetic barrier to resistance is low. 
Daclatasvir (BMS-790052) is the first of DAA targeting against hepatitis C virus NS5A 
showing a very potent antiviral effect on several HCV genotypes. The overall adverse 
event profile is acceptable. Due to a relatively low genetic barrier, combination regimen 
including daclatasvir and other NS3/4A, PEG-IFN/RBV, or NS5B drugs is recommended 
for the treatment of hepatitis C [103]. 
NS5B Inhibitors 
Polymerase inhibitors are another class of DAAs that have recently shown much 
potential. These drugs bind to NS5B polymerase to stop replication of the virus.  
They can be divided into 2 groups: the nucleoside analog inhibitors, that are 
incorporated into the HCV RNA chain, leading to direct chain termination, and the non-
nucleoside inhibitors that bind to several discrete sites outside of the polymerase active 
center, causing a conformational protein change. 
The nucleoside analog inhibitors are potentially active against all HCV genotypes, and 
viral resistance to these agents is low and less frequent than with the non-nucleoside 
inhibitors. 
Sofosbuvir is a nucleoside analog inhibitor and has recently been approved by the US 
Food and Drug Administration. It has a high barrier to viral resistance, and no virologic 
breakthrough has been recorded so far. One major feature of sofosbuvir is its pan-
genotypic antiviral effect [104]. Actually, sofosbuvir has opened the first window for the 
era of “interferon-free” treatment of hepatitis C. Many clinical trials of sofosbuvir are 
now ongoing to optimize the regimen and treatment duration for each HCV genotype. 
 
57 
 
 
4.1.7. Diagnosis   
Diagnosis and management of HCV infection can be achieved through two major types 
of assays: direct methods, that detect viral components (e.g., the core antigen or the 
viral genome) and indirect assays, which detect HCV specific antibodies. 
Indirect diagnosis 
Serologic assays detect HCV specific total antibodies (IgM and IgG) and they are used to 
screen and diagnose HCV exposure. However, these assays do not discriminate between 
active and resolved infections. 
Serological methods can be divided into screening assays and confirmatory methods. 
Screening assays 
Since 1989, when HCV was discovered and its immunodominant epitopes were 
identified, HCV infection has been mainly diagnosed by detecting HCV antibodies from 
serum samples using enzyme immunoassays (EIA). Over time, serologic assays have 
evolved, and current third-generation assays now include multiple recombinant HCV 
antigens from the core, NS3, NS4 and NS5 regions. This has resulted in the reduction of 
the window period and in an overall improved detection of patients exposed to HCV. 
 
 
Fig. 20 A schematic of drugs approved for treating hepatitis C virus (HCV) infection as well as drugs in 
advanced development with tentative future launch dates. PEG-IFN, peglyated-interferon; r, ritonavir 
[106]. 
 
58 
 
Confirmatory assays 
Recombinant immunoblot assays (RIBA) can be used to confirm the presence of HCV 
specific antibodies for individuals who have tested positive by EIA, especially in the 
screening populations with a low prevalence of HCV infection. This assay is highly 
specific, as the presence of antibodies against each of several HCV proteins is assessed 
as individual bands on a membrane strip [106]. 
Direct diagnosis 
The detection of viral components is needed to diagnose an active HCV infection. Direct 
methods include molecular HCV assays and quantification of HCV Core antigen.  
Molecular HCV assays 
Molecular assays to detect the HCV genome are used for several purposes in the clinical 
setting. First, the presence of circulating HCV-RNA reflects viral replication, such that 
sensitive molecular assays (with a lower limit of detection < 50 IU/mL) are used to 
diagnose active HCV infection in patients with a positive antibody test. Second, 
molecular testing is required for an early diagnosis of acute HCV infection, as the HCV-
RNA can be detected before specific antibodies become detectable (within 1-3 weeks 
after exposure). Finally, the diagnosis of a chronic HCV infection is confirmed by the 
presence of both HCV antibodies (with the exception of severely immunosuppressed 
patients) and HCV RNA over 6 months [107]. 
The highly conserved HCV 5’UTR region is the target of choice for HCV genome detection 
across different genotypes. Real-time reverse-transcription PCR (RT-PCR) is the method 
of reference for the quantification of HCVRNA levels in clinical practice according to 
European and American guidelines, given its high sensitivity and wide dynamic range of 
quantification. 
Quantitative tests are also used to monitor antiviral therapy. In order to minimize side-
effects, emergence of resistance and costs, HCV-RNA must be periodically quantified to 
strictly follow treatment stopping rules. 
With the advent of new treatment regimens that include a protease inhibitor and the 
response-guided treatment algorithms, only assays with a lower limit of quantification 
of ≤ 25 IU/mL and a lower limit of detection of approximately 10-15 IU/mL, should be 
used. Additionally, the presence of detectable but not quantifiable HCV-RNA below 
those levels is clinically relevant, as it reflects true viremia [108]. 
HCV Core antigen detection and quantification 
The HCV Core antigen can be detected in the serum of HCV-infected patients, and its 
levels are significantly related to those of HCV-RNA [109]. 
HCV Core assays could be used as an alternative to HCV-RNA assays for three different 
situations:  
(1) to distinguish active from resolved HCV infections;  
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(2) to identify HCV infection in the antibody window period;  
(3) to identify HCV infection in seronegative individuals at high risk for HCV infection, 
such as in hemodialysis patients.  
When HCV infection is confirmed, the following step is the determination of HCV 
genotype, in order to apply the correct therapeutic regimen. 
HCV genotyping assays  
HCV genotype is considered to be the major baseline predictor of a sustained virological 
SVR to IFN-α-based therapy. Moreover, new DAAs (e.g. boceprevir and telaprevir), 
already available, have shown different efficacies on various HCV genotypes. 
While subtyping is not considered to be clinically relevant for PegIFN-α and RBV 
treatment regimens, it may be relevant in the era of directly acting antivirals. 
For instance, subtypes 1a and 1b have been described to have subtype-specific 
resistance profiles to linear protease inhibitors [105]. 
Since the HCV genotype is predictive of the response to, genotyping is mandatory to 
tailor dose and duration of treatment. Furthermore, it is necessary for deciding on triple 
therapy eligibility with currently approved protease inhibitors, which are effective 
against HCV genotype 1. 
The gold standard for HCV genotyping is genome sequencing of the NS5B region and 
subsequent phylogenetic analysis [62]. However, this in-house method is restricted to 
reference centers.  
Actually, many commercial assays for HCV genotyping are available and they are based 
on Real-Time technology or upon RLB technique. 
The target of choice for commercially available genotyping assays has classically been 
the highly conserved 5’UTR. This region allows a well differentiation between several 
HCV genotypes (1 to 7a), except genotype 1 from 6, subtypes c to l. Moreover, 
discrimination among subtypes 1a and 1b is not always reliable using this region. 
Pickett et al. demonstrated that exist two distinct clades within the 1a subtype (clade I 
and II) with each clade having a star-like tree topology and lacking definite correlation 
between time or place of isolation and phylogeny. Identification of significant 
phylogenetically-informative sites at the nucleotide level revealed positions not only 
contributing to clade differentiation, but which are located at or proximal to codons 
associated with resistance to: protease inhibitors (NS3 Q41) or polymerase inhibitors 
(NS5B S368). Synonymous/non synonymous substitution mutation analyses revealed 
that the majority of nucleotide mutations yielded synonymous amino acids, indicating 
the presence of purifying selection pressure across the polyprotein with pockets of 
positive selection also being detected [110]. 
Moreover, Chevaliez demonstrated that the two clades share some nucleotides with 
subtype 1b in the 5’UTR, in particular in positions 107 and 204 (fig. 21). At position 107 
subtype 1a clade I exhibit a G, as subtype 1b, leading to a msidiagnosis. 
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At position 204, A is the most frequent nucleotide for subtype 1a clade I, whereas C is 
the most frequent nucleotide for subtype 1a clade II, and C or T are the most frequent 
nucleotides for subtype 1b. The usual presence of a C at position 204 in subtype 1a clade 
II explains why misclassifications were far more frequent with this clade than with 
subtype 1a clade I [111]. 
 
 
 
 
The analysis of the sole 5’UTR is not sufficient to allow a good discrimination between 
subtypes 1a and 1b, and a differentiation of genotype 1 and 6. Thus, assays targeting 
other regions in addition to the 5′UTR have been recently developed.  
The two regions most frequently chosen for the combined analysis with the 5’UTR are 
NS5b and core regions. They are informative to discriminate subtypes and genotypes 1 
to 6, but also sufficiently conserved to allow primers annealing. 
Commercialized genotyping assays may result in <5% of indeterminate results due to 
the high genetic variability of HCV. Clinicians are forced to treat patients with an 
indeterminate result as if they were infected with genotypes 1 or 4 (resulting in longer 
treatment duration and higher ribavirin doses than for genotypes 2 and 3) and cannot 
decide on triple therapy eligibility. Therefore, patients with an indeterminate genotype 
result should be retested using either an alternative commercial assay or the reference 
method. 
  
Fig. 21 Alignment of the 5’ UTR consensus sequences of subtype 1a clade I (1a-I), subtype 1a clade II (1a-
II) and subtype 1b. Positions 107 and 204, that differentiate subtypes 1a and 1b are in bold [111]. 
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4.2. MATERIALS AND METHODS 
4.2.1. Design of HCV genotyping test prototype 
A prototype for HCV genotyping (AMPLIQUALITY HCV TYPE PLUS) was planned and 
manufactured, after an in silico study for primers and probes selection. 
An approach of two viral regions combined analysis was chosen. The first selected region 
was 5’UTR, because it is the most conserved one and it allows a good discrimination 
between genotypes. The choice of second region was based on bibliographic and 
bioinformatic research. Targets as NS5b, E1 and core were evaluated. NS5b and E1 
regions are too polymorphic for this type of assay. Their high variability could affected 
primers annealing and led to a failure of test. On the other hand, core region contains 
both polymorphic and conserved regions, ideal for primers and genotyping probes 
design. 
The new prototype for HCV genotyping targets 5’UTR and core regions, to allow a good 
discrimination between genotypes 1 to 7a and subtypes 1a and 1b. 
4.2.2. HCV sequences databases 
In order to create a dataset of sequences for each HCV genotype and subtype, suitable 
for the design of specific primers and probes, different databases were used. 
All available HCV partial and whole genome sequences were obtained from: 
1. Virus Pathogen Database and Analysis Resources-ViPR (www.virpr.org) 
2. BLAST tool (www.ncbi.nlm.nih.gov/blast/). 
ViPR is a publicly available database and analysis resource. ViPR integrates data from 
external sources (GenBank, UniProt, Immune Epitope Database, Protein Data Bank), 
direct submissions, internal curation and analysis pipelines. It provides a suite of 
bioinformatics analysis and visualization tools and allows several types of studies on 
pathogenic viruses.  
The Basic Local Alignment Search Tool (BLAST) finds regions of local similarity between 
sequences. The software compares nucleotide or protein sequences to databases and 
calculates the statistical significance of matches. BLAST can be used to infer functional 
and evolutionary relationships between sequences, as well as help identify members of 
gene families. 
Sequences of complete or partial genomes were obtained for all the 7 genotypes and 
for the main subtypes. Each HCV subtype is represented by a certain number of single 
isolates, and this number varies consistently among different subtypes, in particular for 
subtype 1a and 1b, being the most frequent ones. (tab. 18) 
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GENOTYPE/SUBTYPE 
COMPLETE GENOME 
SEQUENCES 
PARTIAL GENOME 
SEQUENCES 
TOTAL OF 
SEQUENCES 
1a 409 3805 4214 
1b 204 4283 4487 
2 (all subtypes) 113 345 458 
3 (all subtypes) 30 1904 1934 
4 (all subtypes) 30 675 705 
5 (all subtypes) 2 72 74 
6 (all subtypes) 17 553 570 
7a - 1 1 
 
Tab.  18 Sequences obtained by ViPR Database, divided on the basis of HCV genotype or subtype. 
 
4.2.3. Design of RT-PCR 
Design of primers 
Design and analysis of primers can be divided into three phases: 
1. Alignment of all available sequences for 5’UTR and core region of the seven 
genotypes. 
2. Design of primer pairs. 
3. Analysis of primers. 
The sequence alignment was performed by using two bioinformatics tools: 
- MUSCLE (Multiple Sequence Comparison by Log-Expectation) algorithm in the 
ViPR database (www.virpr.org), to align sequences belonging from the same 
genotype. 
- ClustalW2 software (www.ebi.ac.uk/Tools/msa/clustalw2/), to align sequences 
belonging from the same subtype. 
Because of high sequences variability, no one software was used for primer design. For 
each alignment, conserved part of sequences were identified as possible regions for 
primer design. Shared sequences between all genotypes were analyzed in order to 
evaluate consensus primers both for the 5’UTR and the core regions. 
Since HCV variability is very high, some isolates cannot be amplified by consensus 
primers, because of high number of SNPs in the sequence. In this case, design of specific 
primers was preferred to degenerate ones.  
Primers analysis was performed by using 3 bioinformatic tools: 
- Primer Express® Software v3.0.1 (Life Technologies); 
- DNA Mate (http://melolab.org/dnaMATE/tm-pred.html);  
- BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi). 
Primer Express® and DNA Mate software were used to analyze melting temperature, 
content of GC, amplicon length and the probability of secondary structures formation. 
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Primers have been also analyzed by using BLAST tool:  
- to avoid no specific alignment with other regions different from the target 
sequence, not only in the HCV genome, but also in other microorganisms and 
human genome; 
- to check if all HCV isolates can be amplified by selected primers or if there was 
some SNP that could affect primer annealing. 
All the selected primers satisfy some common features:  
- specificity for all isolates of the genotype 
- primer length: 20-28bp 
- amplicon length: 200-300bp 
- no dinucleotide repeats or long stretches of guanosine (G) 
- less than 3bp difference in length between primer pairs 
- melting temperatures (Tm) between 65°C and 70°C 
- GC content between 50% and 60% 
- balanced distribution of GC-rich and AT-rich domains 
- no intra-primer homology (more than 3 bases that complement within the 
primer) or inter-primer homology (forward and reverse primers having 
complementary sequences) to avoid self-dimers or primer-dimer formation. 
Sequences of designed primers are not reported, for respecting intellectual proprietary 
and trade secret. 
RNA internal control (IC-RNA) 
Diagnostic assays require an internal control (IC), in order to monitoring the presence of 
inhibitors or other factors which may cause false-negative results. Internal controls are 
used as indicator of good nucleic acid extraction, quality of samples and PCR. In case of 
clinical samples from human, the internal control will indicate the samples have been 
collected, transported and stored properly. An IC for diagnostic RT-PCR assays should be 
easy to produce and to standardize. Additionally, ICs should be stable, noninfectious, 
absent from clinical samples, and suitable for different assays. 
An endogenous IC is a template that occurs naturally within the specimen being 
analyzed. In gene expression analysis and virus screenings, housekeeping genes are 
often used as ICs and references for transcript quantification, but they have to be proven 
for each experiment and target. Exogenous ICs are added before nucleic acid isolation 
(extraction control) or amplification (amplification control), where co-amplification is 
performed within the same reaction. Ideally, these ICs hybridize to the same primers, 
have identical amplification efficiencies, and contain discriminating features, such as 
length or sequence variations, targeted by hybridization probes. However, these 
competitive ICs can lower the amplification efficiency, which results in a lower detection 
limit. Therefore, noncompetitive IC templates are used, where the target and IC are 
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amplified with different primer sets. The disadvantage is that amplification of the IC may 
not accurately reflect amplification of the target. 
For viral nucleic acid amplification tests (NAT), the detection of model viruses, such as 
Escherichia coli bacteriophages, has been described. In these approaches, clinical 
specimens were spiked with a known amount of an animal virus to monitor the 
efficiency of extraction, reverse transcription, and amplification. The advantage of such 
model viruses is the stability of RNA and the control of decapsulation of the viral RNA 
during the extraction procedure [112]. 
Since human serum is not a cellular matrix, the amplification of a housekeeping gene is 
not possible and therefore, the addition of an external amplifiable nucleic acid in the 
PCR assay serves as an internal control. We decide to design, for our assay, an IC able to 
monitoring all the analytical protocol: from viral RNA extraction to strip visualization. 
For this purpose, an E. coli phage was selected as IC. It is resistant to RNase degradation, 
even at high storage temperatures, sufficiently stable for routine use and it does not 
interfere with the multiplex RT-PCR. 
The E. coli phage genome sequence is absent from the human specimens, cell cultures, 
and veterinary samples. The IC is reverse-transcribed and amplified in the same 
multiplex reaction of the target pathogen; primers and relative probe have been 
designed. Our IC did not affected efficiency of amplification.  
Sequences of IC primer pairs and probe designed are not reported, for respecting 
intellectual proprietary and trade secret. 
RT-PCR reaction design 
Reverse transcription polymerase chain reaction (RT-PCR) is one of the variants of 
polymerase chain reaction (PCR). In RT-PCR, the RNA template is first converted into a 
complementary DNA (cDNA) using a reverse transcriptase. The cDNA is then used as a 
template for exponential amplification using PCR.  
This process can be achieved as either a one-step or a two-step reaction. In the one-step 
approach, the entire reaction from cDNA synthesis to PCR amplification occurs in a single 
tube. The one-step approach minimizes experimental variation by containing all of the 
enzymatic reactions in a single environment. However, the starting RNA templates are 
prone to degradation in the one-step approach, and the use of this method is not 
recommended when repeated assays from the same sample is required.  
On the other hand, the two-step reaction requires that the reverse transcriptase 
reaction and PCR amplification be performed in separate tubes. The disadvantage of the 
two-step approach is susceptibility to contamination due to more frequent sample 
handling. 
A multiplex one-step approach was decided for our test. The entire reaction, from RNA 
to amplified products, is made in a single tube, without intermediated manipulations. 
Both reverse transcription and amplification of cDNA are performed by using specific 
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primers for 5’UTR and core HCV regions in a unique reaction. The run time of the 
reaction is 2 hours and 10 minutes; the detailed thermal profile is reported in table 19. 
 
Hold Temperature Time Number of cycles 
Reverse transcription 48°C 30 minutes 1 
HotStart 95°C 10 minutes 1 
Denaturation 95°C 30 seconds 
45 
Annealing and Extension 60°C 90 seconds 
Storage 10°C ∞ 1 
 
Tab.  19 Thermal profile used for the multiplex reverse transcription and amplification of 5’UTR and core 
HCV regions. 
 
Several mixtures of enzymes have been commercially available: these mixes contains 
both the Reverse Transcriptase and the Hot Start Taq polymerase.  
Reverse Transcriptase are active in a range of temperatures between 42°C and 50°C, on 
the basis of their chemical features. Hot Start Taq polymerases are supplied in an 
inactive state and they have no enzymatic activity at room temperature. The enzyme 
remains completely inactive during the reverse-transcription reaction and does not 
interfere with it. This prevents formation of misprimed RT-PCR products and primer-
dimers during reaction setup, reverse transcription and the first denaturation step. The 
enzyme is activated after the reverse-transcription by a denaturation step. The hot start 
also inactivates the Reverse Transcriptase, ensuring temporal separation of reverse 
transcription and PCR, allowing both steps to be performed sequentially in a single tube. 
Several commercial mixtures of enzymes were tested in order to choose the best 
performing reagent that fitted our purpose. Commercial names of reaction mix and 
enzymes, qualitative and quantitative composition of oligomix are not reported, in 
protection of industrial secrecy. 
4.2.4. RLB design 
Design of probes 
Probes have been designed using the alignments of 5’UTR and core regions, previously 
made for primers selection. 
Conserved parts of sequences, delimitated by primers, have been identified both in the 
5’UTR and in the core regions. Among these conserved segments, one sequence in the 
5’UTR and one in the core region were selected for the design of the universal probes. 
These oligos ensure to identify the presence of HCV RNA, even in case of high 
polymorphic sequences. 
Instead, discriminative parts of sequence have been identified to design genotyping 
probes. In the 5’UTR specific probes for all genotypes have been determined, while in 
the core region only probes for subtypes 1a and 1b and genotype 6 have been evaluated. 
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Once defined these regions, 30 nucleotides in length, genotyping probes have been 
designed, by using 3 bioinformatic tools:  
4. DNA Mate (http://melolab.org/dnaMATE/tm-pred.html), to evaluate melting 
temperature. 
5. DNA Folding Form application (http://mfold.rna.albany.edu/?q=mfold), to 
analyze the amplicon folding and to evaluate the presence of possible secondary 
structures that can prevent annealing with probe. 
6. Two state melting application (http://mfold.rna.albany.edu/?q=DINAMelt), to 
evaluate temperature of hybridization between probe and target sequence. 
All the selected probes satisfy some common features:  
- average length of 20 base pairs; 
- designed in regions not involved in strong secondary structures; 
- 50°C as temperature of hybridization with specific sequences; 
- average temperature of melting between 60° and 65°C. 
Sequences of probes are not reported, in protection of industrial secrecy. 
 
gi_254546399_4d   CCGGAATCGCCGGGACGACCGGGTCCTTTCTTGGA-TAAACCCGCTCAAT 149 
gi_239836688_4d   CCGGAATCGCCGGGATGACCGGGTCCTTTCTTGGAT-AAACCCGCTCAAT 149 
L29625_4e       CCGGAATCGCCGAGATGACCGGGTCCTTTCTTGGA-TCAACCCGCTCAAT 126 
L29591_4e         CCGGAATCGCCGAGATGACCGGGTCCTTTCTTGGA-TCAACCCGCTCAAT 126 
EF115679_4e       CCGGAATCGCCGAGATGACCGGGTCCTTTCTTGGA-TTAACCCGCTCAAT 121 
Gi_239836676_4f   CCGGAATCGCCGGGACGACCGGGTCCTTTCTTGGA-TAAACCCGCTCAAT 149 
gi_254546397_4f   CCGGAATCGCCGGGACGACCGGGTCCTTTCTTGGA-TTAACCCGCTCAAT 149 
gb_JX227963.1_4g  CCGGAATCGCCGGGACGACCGGGTCCTTTCTTGGAACAAACCCGCTCAAT 138 
EF115673_4h       CCGGAATCGCCGGGATGACCGGGTCCTTTCTTGGAACTAACCCGCTCAAT 122 
gi_239836678_4k   CCGGAATCGCCGGGACGACCGGGTCCTTTCTTGGAACAAACCCGCTCAAT 150 
gi_239836690_4k   CCGGAATCGCCGGGATGACCGGGTCCTTTCTTGGAACTAACCCGCTCAAT 150 
gi_239836692_     CCGGAATCGCCAGGACGACCGGGTCCTTTCTTGGATTAACCCGCTCAATG 149 
gb_JX227958.1_4L  CCGGAATCGCCGGGATGACCGGGTCCTTTCTTGGA-TCAACCCGCTCAAT 137 
gb_JX227957.1_4L  CCGGAATCGCCGGGATGACCGGGTCCTTTCTTGGA-TTAACCCGCTCAAT 135 
gi_239836680_4m   CCGGAATCGCCAGGACGACCGGGTCCTTTCTTGGATCAAACCCGCTCAAT 150 
gb_JX227972.1_4m  CCGGAATCGCCAGGACGACCGGGTCCTTTCTTGGATTAAACCCGCTCAAT 138 
gb_JX227961.1_4m  CCGGAATCGCCAGGACGACCGGGTCCTTTCTTGGATCAACCCGCTCAATG 138 
gb_JX227970.1_4n  CCGGAATCGCCGGGATGACCGGGTCCTTTCTTGGA-TTAACCCGCTCAAT 137 
gi_239836696_4n   CCGGAATCGCCGGGATGACCGGGTCCTTTCTTGGA-TCAACCCGCTCAAT 148 
gb_JX227979.1_4o  CCGGAATCGCCGGGACGACCGGGTCCTTTCTTGGAACAAACCCGCTCAAT 97 
gb_JX227978.1_4o  CCGGAATCGCCGGGACGACCGGGTCCTTTCTTGGAACAAACCCGCTCAAT 97 
gi_239836682_4q   CCGGAATCGCCGGGATGACCGGGTCCTTTCTTGGAACAAACCCGCTCAAT 150 
gb_JX227976.1_4r  CCGGAATCGCCAGGACGACCGGGTCCTTTCTTGGATTAACCCGCTCAATG 138 
gb_JX227962.1_4r  CCGGAATCGCCAGGACGACCGGGTCCTTTCTTGGATTAACCCGCTCAATG 138 
gb_JX227960.1_4v  CCGGAATCGCCGGGATGACCGGGTCCTTTCTTGGAATAAACCCGCTCAAT 101 
gb_JX227959.1_4v  CCGGAATCGCCGGGATGACCGGGTCCTTTCTTGGAACAAACCCGCTCAAT 148 
SEQ_AB_BEP051038  CCGGAATCGCCGGGATGACCGGGTCCTTTCTTGGAT-AAACCCGCTCAAT 112 
Probe   CCGGAATCGCCAGGACGACCGGGTCCTTTCTTGGA--------------- 35 
                  ***********  ** *******************                            
 
 
  
Fig. 22 Example of alignment between several genotype 4 isolates and selection of a discriminative region 
for probe design. 
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Strip manufacturing 
The support of the strip is a nitrocellulose baked membrane. The probes are spotted on 
nitrocellulose through an automatic work-station and then are immobilized on support 
by exposure to UV light, which induces the covalent bounds between oligos and 
membrane. 
Then, spotted membrane is incubated with a blocking solution containing BSA, for 30 
minutes in moderate shaking. This step prevents non-specific background binding of the 
DNA to membrane. 
Finally, membrane is cutted into single strips, through an automatic instrument. 
Probes concentration, buffer compositions, commercial name of nitrocellulose 
membrane and other details are omitted, for respecting intellectual proprietary and 
trade secret. 
Design of RLB protocol 
A RLB assay is influenced by several interconnected parameters. 
The stringency of the assay could be achieved by acting on two fundamental factors: 
temperature and ionic strenght of solutions. It is also possible to vary incubation time of 
the several washing steps. 
Table 20 summarizes the RLB protocol of our genotyping test. 
 
Tab.  20 Scheme of protocol for visualization on strip. 
STEP REAGENTS INCUBATION 
TIME OF 
INCUBATION 
1) Denaturation of 
amplicon 
Amplicon + Denaturation Solution, 
containing Sodium hydroxide 
Room temperature 5’ 
2) Hybridization 
Hybridization solution, containing Sodium 
citrate, Sodium chloride, Sodium dodecyl 
sulfate and preservatives 
50°C 
Moderate shaking 
1 h 
3) Stringent wash 
Stringent wash solution, containing Sodium 
citrate, Sodium chloride, Sodium dodecyl 
sulfate, and preservatives 
50°C 
Moderate shaking 
2’ 
5) Incubation with 
Streptavidine AP-
Conjugated 
Streptavidine AP-Conjugated diluted in 
stringent wash solution 
50°C 
Moderate shaking 
15’ 
6) Wash 
Rinse solution, containing magnesium 
chloride, sodium chloride, Trizma and 
detergents. 
Room temperature 
Moderate shaking 
2’ 
7) Wash 
Rinse solution, containing magnesium 
chloride, sodium chloride, Trizma and 
detergents. 
Room temperature 
Moderate shaking 
2’ 
8) Colorimetric reaction 
NBT/BCIP solution, containing NBT, BCIP, Tris 
buffer and MgSO4 
Room temperature 
Moderate shaking 
AT DARK LIGHT 
10’ 
9) Blocking of reaction Blocking solution, containing Citric acid 
Room temperature 
Moderate shaking 
2’ 
10) Final wash Distilled water 
Room temperature 
Moderate shaking 
2’ 
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4.2.5. Sequencing  
NS5b sequencing is still the gold standard method for HCV genotyping.  
In order to confirm results of RLB subtyping, NS5b sequencing of genotype 1 samples 
was performed. 
RT-PCR was made with specific primers for NS5b region, previously reported by Sandres-
Sauné et al. [113]; the same enzyme mix utilized for our HCV genotyping test was used, 
but with a different thermal profile, that fitted to melting temperature of these primers. 
Table 21 summarizes thermal profile used for NS5b amplification. 
 
Hold Temperature Time Number of cycles 
Reverse transcription 48°C  30 minutes 1 
HotStart 95°C  10 minutes 1 
Denaturation 95°C 30 seconds 
40 Annealing 52°C  60 seconds 
Extension 60°C 60 seconds 
Storage 10°C  ∞ 1 
 
Tab.  21 Thermal profile of NS5b sequencing. 
 
Amplified products have been purified by using ExoSap-IT® (Affymetrix), according to 
the manufacturer’s protocol. Reaction of sequencing was performed by BMR Genomics, 
with the BigDyes terminator cycle sequencing kit v3.1 (Applied Biosystems). The 
sequencing reactions were run on ABI 3730XL (Applied Biosystems) and ABI 3100 
(Applied Biosystems) and were analyzed with FinchTV software v1.4 (Geospiza).  
4.2.6. Samples 
Clinical samples used in this study have been provided by the Molecular Hepatology 
Laboratory of VIMM (Venetian Institute of Molecular Medicine, Padova). Samples have 
been selected and afterwards they were made anonymous, randomized, classified and 
stored with a biobanking system. 
All human serum samples were previously analyzed for detection of HCV RNA with a 
Real Time PCR system by the Molecular Hepatology Laboratory: 212 samples were 
positive for HCV RNA and 71 were negative (tab. 22).  
The 212 HCV positive samples were representative of genotypes 1, 2, 3 and 4; they also 
reflected different stages of viral infection, characterized by different viral loads. 
For the less common genotypes 5, 6 and 7a, commercial synthetic controls were used 
(tab. 22). The AcroMetrix® HCV Control (Life Tecnologies) has been carefully formulated 
to mimic naturally occurring human specimens containing HCV RNA. They are prepared 
by quantitatively diluting HCV positive human serum or plasma of a specific genotype 
into normal human plasma (NHP). The NHP was previously tested and found to be non-
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reactive for antibodies to HIV-1, HIV-2, HTLV-I-II, and HCV, HIV1-RNA, HBsAg, HBV DNA, 
HCV RNA, WNV RNA and CMV DNA. Each control contains HCV RNA calibrated against 
the WHO International Standard for HCV RNA, which is genotype 1. The final viral load 
of these controls is about 2x104 IU/mL. 
In this study, we have used AcroMetrix® controls for genotypes 5a and 6a. 
For the other rare subtypes of genotype 6 (6c, 6d, 6e, 6l and 6n) and for genotype 7a, 
plasmids pEX-A2, containing both 5’UTR and core sequences, were provided by Eurofins 
genomics. 
They were quantified and diluted to a final concentration of 104 c/μL. 
 
Number Matrix HCV 
212 Human serum positive 
71 Human serum negative 
2 Synthetic serum added with HCV 
(Acrometrix® controls) 
positive 
6 Synthetic DNA controls 
(Eurofins genomics plasmids) 
positive 
 
Tab.  22 List of samples used in the evaluation study 
 
4.2.7. RNA extraction  
Total RNA was extracted from both clinical and synthetic human serum, by using the 
BioRobot EZ1 DSP system, with the EZ1 DSP Virus kit (QIAGEN, Hilden, Germany), 
according to the manufacturer’s instructions. 
RNA was extracted from 400 μL of human serum and it was eluted in 60 μL. 
In order to monitoring the efficiency of extraction, 10 μL of internal control was also 
added during the elution step of RNA, according to the manufacturer’s instructions. 
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4.3. RESULTS 
4.3.1. OPTIMIZATION OF HCV GENOTYPING TEST PROTOTYPE 
In this Ph. D. project, we have developed a prototype for a new HCV genotyping test, 
named AMPLIQUALITY HCV TYPE PLUS, with the 5’UTR and core as target regions. 
Preliminary experimental tests have been made to set conditions of RT-PCR and 
visualization on strip. During the optimization phase of the project, these conditions 
were tested with a subset of 50 samples selected for their positivity to different 
genotypes, with different viral load. This evaluation phase shows a randomly failure of 
the test. Therefore, a series of experiments was planned in order to investigated the 
cause. 
Evaluation of enzyme mixture 
Different commercial mix were tested to select the best performing enzyme mixture for 
RT-PCR. Testing experiments were planned in order to achieve the major intra-assay 
variability: samples with different viral loads and various genotypes were used. Tests 
were made in parallel, to lower variability of other factors, that can affect result. 
We also evaluated the introduction of an enhancer solution (constituted by DMSO) to 
avoid the typical secondary structures of RNA, and to increase the RT-PCR efficiency. 
However, the enhancer solution did not led to the expected amplification improvement, 
but conversely it seemed to have a sort of inhibition effect. (fig. 23) 
 
Evaluation of RT-PCR efficiency  
We optimized the multiplex amplification reaction step by step, in order to obtain a good 
amplification of both the target regions: 5’UTR and Core. 
Indeed, the two regions showed an impaired amplification efficiency, with the 
prevalence of 5’UTR on core. The 5’UTR region was always correctly amplified, instead 
in some samples, the core amplification failed. 
MW     1         2        3         4 
Fig. 23 Imagine of agarose gel visualization of core region simplex PCR, performed on two different RNA 
samples, without and with the adding of the enhancer. The amplified product has a length of 280 bp. 
Legend: MW Molecular Weight (501-489, 404, 331, 242, 190, 147, 111-110, 67, 34-34, 26 bp), 1= sample 
1, mix without enhancer; 2= sample 1, mix with enhancer; 3= sample 2, mix without enhancer; 4= sample 
2, mix with enhancer. 
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One hypothesis was the absence of binding between probes and amplicon of core 
region, caused by the possible formation of secondary structures.  The visualization of 
PCR products by gel electrophoresis showed that the band of core region (280 bp) was 
not present. This result demonstrated that there was a problem in the RT-PCR set up. 
The relationship between this PCR failure and samples viral load or storage condition 
(i.e. number of freeze and thaw cycles) were excluded, because of the random way with 
which it occurs. 
Once excluded these factors, we have focused our attention on the primers efficiency. 
We decided to perform a simplex PCR reaction with synthetic DNA for genotype 1 and 6 
to investigate the primers efficiency. Results showed that primers for 5’UTR worked well 
and had a good signal on strip, while those for core led to results of less intensity. 
Therefore, we decided to test the effect of increasing the PCR annealing temperature, 
by experiments with gradient tool. The current annealing temperature of 52° was 
increased to 60°C (fig. 24). 
 
 
 
 
 
 
As shown in fig. 24, the intensity of core amplification product was less with the 
annealing temperature of 52° and get better in combination with increasing of 
temperature. 
A similar experiment with gradient tool, showed that also annealing temperature of 
5’UTR primers could be increased at 60°C without impairment (data not shown). 
Therefore, the annealing temperature of 60°C was selected as a good compromise for 
the efficient amplification of both viral regions.  
HCV RNA positive samples were tested with the new annealing condition of reverse-
transcription. The reaction was yet not proficient for all the samples tested, and 
randomly the core amplification has continued to fail. 
 
MW     1         2        3         4        5        6         7        8 
Fig. 134 Imagine of agarose gel visualization of core region simplex PCR, performed on synthetic DNA for 
genotype 1, with gradient tool. The amplification product has a length of 280 bp. Legend: MW Molecular 
Weight (501-489, 404, 331, 242, 190, 147, 111-110, 67, 34-34, 26 bp), 1= annealing temperature of 52.0°C, 
2= 52.5°C, 3= 53.5°C, 4= 54.9°C, 5= 56.8°C, 6= 58.4°C, 7= 59.4°C, 8= 60.0°C. 
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Primers evaluation and redesign 
At the beginning of this study, primers have been newly designed on a dataset 
containing all the available sequences for HCV genotypes and major subtypes. This 
bioinformatics study has taken long time and led to a design of a primer set for HCV 
5’UTR and core regions. Moreover, primers for amplification of the internal control, an 
E. coli phage, were evaluated. 
The entire set is constituted by several primers, because of the high variability of HCV 
sequences. Specific primers, covering all SNP, were preferred to degenerate primers 
that can impair RT-PCR efficiency.  
Because of the continues random failure of the multiplex reaction, even though efforts 
made for RT-PCR set up, we decided to modify the primers sequence. For the new 
design, the same position in the viral genome was more or less maintained, but certain 
number of nucleotides down or upstream were shifted respect the old localization. 
Newly designed primers were tested with the selected amplification conditions 
(annealing temperature of 60°C) and they led to good results with all samples of the 
subset. 
Starting materials evaluation 
During the optimization phase, also the amount of RNA used in RT-PCR was 
standardized. 
Initially we have tried to solve the random failure of amplification by increasing the 
quantity of RNA, added in RT-PCR, to a final volume of 20 μL. The results were not clear, 
because a major amount of RNA lead to a good results in some samples, but has an 
inhibitory effect on others.  
At the end the use of 10 μL of RNA extracted from 400 μL of human serum was 
established as best condition. 
Evaluation of genotyping strip 
The layout of HCV genotyping strip, obtained at the end of the optimization phase of 
this project, is shown in fig 25. The first part of the strip is dedicated to 5’UTR region and 
it contains 16 probes, able to recognize genome sequence of genotypes 1-7a. A detailed 
description of these probes is shown in table 23. 
The bottom part of the strip is reserved to core region, and has three specific probes 
respectively for HCV 1a and 1b subtypes and for genotype 6. This part of the strip must 
be considered only in presence of a genotype 1 pattern obtained in the 5’UTR. A detailed 
description of these probes is shown in table 24. 
Every strip also contains 4 control lines: 
- Internal control line, that hybridizes IC amplification product and allows the user 
to monitor the success of extraction and RT-PCR procedure; 
- Staining control line, that guarantee the correct execution of post-hybridization 
steps; 
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- Universal 5’UTR line, that hybridizes amplification product of this region; 
- Universal core line, that hybridizes amplification product of this region and must 
be evaluated only in presence of a genotype 1 pattern obtained in the 5’UTR 
region. 
 
Probe Number Description 
1 Identification of HCV 1 genotype 
2 Identification of HCV 1 genotype 
3 Identification of HCV 1b subtype 
4 Identification of HCV 1b subtype 
5 Identification of HCV 1a subtype 
6 Identification of HCV 2 genotype 
7 Identification of HCV 2a/2c subtype 
8 Identification of HCV 2b subtype 
9 Identification of HCV 3 genotype 
10 Identification of HCV 3a subtype 
11 Identification of  HCV 3h subtype 
12 Identification of HCV 4 genotype 
13 Identification of HCV 4a subtype 
14 Identification of HCV 4r and 4m subtypes 
15 Identification of HCV 5 genotype, subtype a 
16 Identification of HCV 6 genotype, subtype a and b 
 
Tab.  23 Probes for 5’UTR genotyping and their specificity. 
 
 
Probe Number Description 
17 This probe is specific for HCV 1a subtype 
18 This probe is specific for HCV 1b subtype 
19 This probe identifies HCV 6 genotype, all subtypes 
 
Tab.  24 Probes for core genotyping and their specificity. 
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Strip results interpretation 
The results of the genotyping test is not immediate to understand, because more probes 
give a signal for the same genotype. Therefore, every genotype can have more patterns 
of bands, due to the high sequence variability of HCV genome. 
Moreover, even if each probe is specific for a certain genotype or subtype, it could led 
to a signal also for others, because of cross-reactivity of oligos. Some SNP differences 
did not affected annealing between probe and amplified products, because they are 
located at the extremity of the probe.  
The bioinformatics analysis led us to create a series of putative hybridization patterns of 
HCV isolates, determined by this set of probes.  
In order to simplify the interpretation procedure, we have decided that the analysis of 
core region must be considered only in presence of a genotype 1 pattern obtained in 
the 5’UTR. Probes designed in the 5’UTR, alone are not able to correctly subtype all 
genotype 1 samples, but there are not problems for subtyping genotype 2, 3, 4 and 5. 
Moreover, subtypes 6a and 6b can be discriminated in the 5’UTR, because the 
hybridization pattern is well defined, but subtypes 6c to 6n show the same profile 
Fig. 25 Scheme of strip layout. 
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pattern of genotype 1. In this case, the analysis of 5’UTR alone is not sufficient and the 
core region information are needed to avoid a misdiagnosis. 
This complicated situation makes necessary the use of a tool for strip interpretation. For 
this reason an interpretation chart were developed, as shown in fig. 26. 
For each genotype, several probe patterns were identified, as reported in table 25. 
 
Genotype Number of patterns (5’UTR) 
1 23 
2 13 
3 8 
4 38 
5 2 
6 5 
7a 4 
 
Tab. 25 Number of band patterns reported in the interpretation chart for each genotype. 
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Fig.  26 Part of the interpretation chart, relative to patterns of genotypes 1 and 6. On the left genotype 1 and 6 patterns in the 5’UTR, on the right patterns relative to core 
region
 
77 
 
Evaluation of RLB protocol 
A series of tests were performed in order to achieve a triple objective: the 
standardization of RLB protocol, the presence of a good signal and the absence of 
background. Different combination of hybridization and washing solutions, by 
modulating level of stringency, were tried. The final formulation obtained allow results 
with well defined bands on strip and absence of aspecific signals. 
4.3.2. VALIDATION OF HCV GENOTYPING TEST PROTOTYPE 
After achieving the prototype standardization of HCV genotyping test, a phase of the 
project dedicated to the evaluation of the diagnostic performance was started. As 
requested by the Common Technical Specifications for in vitro diagnostic medical devices 
(2009) for the test validation, the following parameters were investigated: diagnostic 
specificity and diagnostic sensitivity. 
Diagnostic specificity 
Diagnostic specificity is the conditional probability that a person not having a disease 
will be correctly identified by a clinical test. It is calculated from the number of true 
negative results divided by the total number of those without the disease (which is the 
sum of the numbers of true negative plus false positive results).  
Diagnostic specificity of our assay was assessed by the evaluation of 71 negative samples 
for HCV RNA. As reference method another CE in vitro dispositive, that target the 5’UTR 
alone, was used. 
All the samples were negative with our genotyping test and results were concordant 
with reference method (fig. 27). 
Therefore, our HCV genotyping test shows a diagnostic specificity of 100%. 
 
 
 
Fig. 27 Comparison of results obtained with AMPLIQUALITY HCV TYPE PLUS (5’UTR and core) and with 
reference method (5’UTR alone). 
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Diagnostic sensitivity 
Diagnostic sensitivity is the conditional probability that a person having a disease will be 
correctly identified by a clinical test. It is calculated from the number of true positive 
results divided by the total number with the disease (which is the sum of the numbers 
of true positive plus false negative results).  
Diagnostic sensitivity of our genotyping test was defined by the evaluation of 220 
positive samples, considering both clinical and synthetic ones. 
The major part of samples had HCV genotype 1 (n=145, 66%), reflecting the worldwide 
distribution of viral strains. In Italy, genotype 1 is largely diffused and it is not so difficult 
recruiting patients with this HCV genotype. Instead, genotypes 2, 3 and 4 are less 
common and samples with these strains are rare. 
Genotype 5, 6 and 7a are the less represented, because of their epidemiological 
distribution. In Europe genotypes 5 and 6 are extremely rare, they are prevalently 
diffused in Southern Africa and East Asia. Thus, the availability of these particular 
samples is very limited.  
On the other hand, genotype 7a was officially classified only in January 2014, by the 
publication of consensus classification of HCV variants by Smith et al. [63]; only one 
genotype 7 infection has been reported and it was isolated in Canada from a Central 
African immigrant [71]. 
Therefore, for genotypes 5 and 6a, we have used Acrometrix® synthetic controls (human 
serum added with HCV, at a final viral load of 2 x 104 IU/mL). While, for subtypes 6c, 6d, 
6e, 6l, 6n and genotype 7a, we were forced to use synthetic customized DNA control, to 
check efficiency of primers and probes. 
 
 
 
Genotype 1
65,9%
Genotype 2
18,6%
Genotype 3
5,5%
Genotype 4
6,4%
Genotype 
5
0,5%
Genotype 
6
2,7%
Genotype 7a
0,5%
Fig. 28 Distribution of samples in relation to their genotype. 
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Samples used in this study showed different viral loads, included in a range between 1 x 
103 and 6 x 107 IU/mL. The major part of samples fell into the range > 500.000 IU/mL e 
< 5.000.000 IU/mL.  
We have also 37 samples with an elevated viral load, useful to determine possible 
impairment of reaction due to high amount of RNA. Instead, we had only 4 samples with 
a viral load lower of 5000 IU/mL. We had no data about viral loads of 14 samples. 
Figure 29 summarizes the distribution of samples in relation to viral load. 
 
 
 
Fig. 29 Distribution of samples in relation to viral load. 
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First, diagnostic sensitivity was assessed at genotype level. Results obtained with our 
test were compared to those achieved with the reference method, the assay that target 
the 5’UTR alone. Discrepant results were confirmed by NS5b sequencing, as second 
reference method. 
 
Genotype 
5’UTR + core 
(AMPLIQUALITY 
HCV TYPE PLUS) 
Sole 5’UTR 
(1st reference method) 
NS5b sequencing 
(2nd reference method) 
1 143 148 143 
2 41 41 n.a. 
3 12 12 n.a. 
4 14 14 n.a. 
5 1 1 n.a. 
6 6 1 n.a. 
7 1 1 n.a. 
 
Tab.  26 Comparison of genotyping results obtained with different methods. Total of genotyped samples 
is 218, because of 2 samples RT-PCR failure. 
 
The concordance between the two genotyping methods was 97.7%. Samples with 
genotype 2, 3, 4, 5 and 7 were identified in the same way, while for genotype 1 and 6 
there were some discrepancy. 
Sequencing of NS5b region of samples with discrepant results had confirmed the 
AMPLIQUALITY HCV TYPE PLUS genotyping. This allow to calculate for our assay a 
diagnostic sensitivity, at genotype level, of 100%. 
Furthermore these data demonstrate that the 5’UTR alone is not able to discriminate 
between genotype 1 and 6, subtypes c-n; the resulting pattern of band on strip is the 
same of a genotype 1, leading to a misdiagnosis. Combining the analysis of 5’UTR and 
core regions, a discrimination between these genotypes is allowed, as shown in fig. 30. 
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Then we have calculated diagnostic sensitivity at subtype level, in particular for 
genotype 1.  
Results obtained with our test were compared to those achieved both with the 
genotyping of the sole 5’UTR and NS5b sequencing.  
Regard samples infected by subtype HCV 1a, results obtained with our assay are similar 
to those of NS5b sequencing. Two samples were not genotyped, because of failure of 
RT-PCR. 
The analysis of 5’UTR alone led to a correct subtyping only for 20 samples (44.4%); other 
19 samples (42.2%) were not subtyped and defined only as genotype 1. Four samples 
(8.9%) were wrongly identified as subtype 1b (tab. 27). 
Regard samples infected by subtype HCV 1b, results obtained with our assay are similar 
to those of NS5b sequencing. One sample was not genotyped, because of failure of RT-
PCR. 
The analysis of 5’UTR alone led to a correct subtyping of 92 samples (92%); other 3 
samples (3%) were not subtyped and defined only as genotype 1. Instead, 4 samples 
(4%) were wrongly identified as subtype 1a (tab. 28). 
5’UTR probes 5’UTR probes 
Core probes 
A. B. 
Fig. 30 Imagine of strip result for a genotype 6 sample.  
A. Strip relative to the analysis of sole 5’UTR: band pattern identifies a 1b isolate, leading to a 
misdiagnosis.  
B. Strip relative to combined analysis 5’UTR and core: band pattern of core region identifies a genotype 
6 isolate. (see interpretation chart page 76) 
Staining control Staining control 
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Combining the analysis of 5’UTR and core regions, a discrimination between these 
subtypes is allowed, as shown in fig. 31. 
In conclusion, our HCV genotyping test shows a diagnostic sensitivity, at subtype level, 
of 100%.  
 
Genotype 
5’UTR + core 
(AMPLIQUALITY 
HCV TYPE PLUS) 
Sole 5’UTR 
(1st reference method) 
NS5b sequencing 
(2nd reference method) 
1a 43 20 45 
1b 0 4 0 
1 0 19 0 
No genotyping 2 2 0 
Tot 45 45 45 
 
Tab.  27 Comparison of subtyping results obtained with AMPLIQUALITY HCV TYPE PLUS assay and the two 
reference methods. 
 
 
Genotype 
5’UTR + core 
(AMPLIQUALITY 
HCV TYPE PLUS) 
Sole 5’UTR 
(1st reference method) 
NS5b sequencing 
(2nd reference method) 
1b 99 92 100 
1a 0 4 0 
1 0 3 0 
No genotyping 1 1 0 
Tot 100 100 100 
 
Tab.  28 Comparison of subtyping results obtained with AMPLIQUALITY HCV TYPE PLUS assay and the two 
reference methods. 
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D. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
>gb|FJ024281.1|  Hepatitis C virus subtype 1a isolate HCV-1a/US/BID-V1718/2007,  
complete genome 
Length=9301 
 
Score =  501 bits (271),  Expect = 1e-138 
Identities = 302/317 (95%), Gaps = 2/317 (0%) 
Strand=Plus/Plus 
  
Staining control Staining control 
5’UTR probes 
5’UTR probes 
Core probes 
Fig. 31 Comparison of results obtained with the 3 genotyping methods for a misdiagnosed sample.  
A. Strip relative to the analysis of sole 5’UTR: band pattern identifies a 1b isolate, leading to a misdiagnosis. 
B. Strip relative to combined analysis 5’UTR and core: band pattern of core region identifies a subtype 1a 
isolate. (see interpretation chart page 76) 
C. Electropherogram relative to NS5b sequence of the sample. 
D. BLAST result relative to NS5b sequence: sample is confirmed to be subtype 1a. 
A. B. 
C. 
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5. DISCUSSION AND CONCLUSIONS 
Reverse Line Blot is rapidly becoming a standard molecular tool for diagnostic and 
epidemiological studies in an increasing number of laboratories all over the world, 
thanks to its high grade of usability. RLB is a simple technique that can be used in 
diagnostic routine also by small laboratories, because the request instruments are few 
and not expensive. 
The technique can be utilized in a number of ways. Multiple probes can be designed to 
detect sequence variation within a single amplified product, or multiple targets can be 
amplified simultaneously, with one (or more) probes used for subsequent detection. A 
combination of both approaches can also be used within a single assay. The ability to 
include multiple probes for a single target sequence makes the assay highly specific. The 
flexibility of the method allows its use for a wide range of applications. 
The aim of our project was the development of RLB tests and the evaluation of their 
application in the management of diseases, requiring a genetic characterization.  
In the first part of the study we explore the potentiality of RLB in detecting known 
genetic mutations in the human genome and our interest was focused on atypical CF. 
This is a rare genetic disease, not well genetically characterized and probably related to 
the presence of mutation in the ENaC genes, as discussed in recent epidemiological 
studies [58, 59]. Until today, only sequencing approach was used for investigate the 
presence of specific ENaC mutations, and this limiting the diffusion of this type of 
investigation. 
We developed GENEQUALITY ENaC-TYPE, which is a device based on RLB, able to detect 
9 ENaC variants, previously identified by sequencing works of Sheridan and Azad.  
Once defined and analytically validate the prototype, the assay has been evaluated on 
a series of patients with atypical CF, in collaboration with Laboratory of Molecular 
Pathology, Department of Pathology and Diagnostics, University Hospital of Verona, a 
reference center for cystic fibrosis. 
Two groups of patients were selected on the basis of their different CF phenotypes: 
lungs disease vs. pancreatic manifestation and the results were separately analyzed. 
Until now, studies about correlation of ENaC mutations with atypical cystic fibrosis have 
been performed only on atypical CF patients with respiratory symptoms and not on 
individuals with different CF phenotypes. 
In the group of lungs disease phenotypes, four significative variants were detected 
(p.E539K-SCNN1B, p.1670-2A>G-SCNN1B, p.P267L-SCNN1B and p.G294S-SCNN1B). 
Mutations were found at a more than five-fold significantly increased in patients (5.5%) 
respect to the controls (0%).  
Patients that carried these variants were heterozygous for CFTR mutations. Thus, about 
50% of the CFTR network is still functional. However, the remainder 50% may be 
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rendered nonfunctional by a mutation in at least one other member of the network, 
such as ENaC. 
In the group of pancreatic disease phenotypes, none ENaC mutation showed a 
frequency significantly higher in patients rather than in controls. 
Despite CFTR, which expression and activity in pancreatic cells have been well 
established, ENaC role in pancreas is still an argument of controversial opinions. Findings 
of several studies are in contrast about presence of functional ENaC in pancreatic cells 
and the possible physiologic function of ENaC, therefore, remains obscure. Thus, it is 
impossible to define if our results are due to lack of ENaC involvement in the 
pathogenesis of CF-like pancreatic disorders or to absence of functional channels in 
pancreatic cells. 
RLB method is limited to the detection of specific ENaC mutations; functional analysis of 
each variants has not been performed. Thus, it is impossible to develop an explanation 
of the effect of the different mutations, especially in the light that either too low or too 
high amounts of ENaC can already result in two different diseases, which will be even 
further complicated if the CFTR protein is implicated.  
Despite classic CF in which a large part of CFTR causative mutations has been defined, 
role of ENaC variants in atypical cystic fibrosis is still to be defined. Studies about 
prevalence of ENaC mutations in patients with CF-like disorders are very few and the 
causative relationship between ENaC and disorder is only supposed. Phenotypes of 
atypical CF are very wide, suggesting an implication of additional genes/proteins and 
environmental factors. Indeed, in a considerable number of these patients no 
involvement of ENaC was found. 
Our test has demonstrated to be easily applied to a diagnostic routine, for his usability 
and simple results interpretation but it allows detection of only 9 specific variants. In a 
context of undefined correlation, this test is too limited. Further studies of sequencing 
of all exons and exon/intron junctions have to be performed on patients with different 
CF-like disorder, to collect more data. Then, functional studies will clarify effect of 
identified variants on phenotype.  
Therefore, this test at the moment could not be used as a confirmatory assay for 
diagnosis and management of therapy. Probably our assay could find a collocation in the 
epidemiological field, to evaluate prevalence of the 9 variant in particular group of 
individuals. Moreover, we think that this study has given preliminary results that could 
be achieved for a future work based on a more advanced technology, such as Next 
Generation Sequencing. For example, we have seen that study could be performed on 
patients with CF-like lungs disorder and not on individuals with pancreatic pathology. 
Moreover, it could be interesting to evaluate prevalence of ENaC variants in patients 
with CBAVD, one of the major related CF pathologies. 
We have defined that RLB is not the ideal approach for studying a genetic disease with 
so many obscure points. On the other hand, this technique is appropriate for diagnosis 
of disorder in which causative mutations have been well defined, e. g. classic CF. In this 
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case RLB is a very useful method that allow contemporary detection of principal 
mutations in each individual. Each strip can contain more diffuse mutations and regional 
variants. This could be a test of first analysis, to screen a part of patients. 
In the second part of the study, we explore the potentiality of RLB in the identification 
of the genotypic strand of Hepatitis C virus. Genotypes differ at 31-34 % of nucleotide 
positions of complete genomic sequences with approximately 30% amino acid sequence 
divergence. 
HCV genotype is one of the factor influencing the disease progression and the major 
predictor of a SVR to double therapy peg-IFN/ribavirin. SVR vary according to the HCV 
genotype involved. HCV genotype 1 and 4 were found to be the prevalent resistant 
genotypes. Moreover, new DAAs have shown different efficacy on subtypes 1a and 1b, 
due to different resistance profile of these subtypes. Thus, HCV genotyping is essential 
to apply the most appropriate therapeutic regimen. 
The gold standard for HCV genotyping is NS5b sequencing and subsequent phylogenetic 
analysis. Generally, this type of assay is used by reference centers, which design home-
made protocols, based on their specific required. Therefore, other type of assay, based 
on Real-Time PCR or RLB technologies, are commercially available. The major part of 
them target the viral 5’UTR, because it is the most conserved one. This region is able to 
well differentiate the virus at the genotype level, except for genotype 1 and 6 (subtypes 
c to l). Moreover, it cannot lead to the subtyping genotype 1, because the HCV subtype 
1a segregates in two distinct clades, which are termed 1a clade I and 1a clade II. The 
5’UTR sequence of 1a clade I is identical to that of subtype 1b. Recent study shows that 
using the sole 5’UTR as target for genotyping, there is a mistyping approximately of 25% 
and 10% of HCV subtype 1a and 1b strains, respectively [111]. 
Therefore, it is evident that the analysis of the sole 5’UTR is not sufficient to allow a good 
determination of HCV genotype/subtype and that evaluation of another region is 
necessary.  
The AMPLIQUALITY HCV TYPE PLUS device designed and developed during the second 
part of this project is an RLB assay which can well differentiate genotype 1 to 6 and 
subtypes 1a and 1b, thanks to the presence of core as target region in addition to 5’UTR.  
We selected the core gene because it contains both conserved and variable regions and 
this condition is optimal for designing primers and probe, respectively. 
The optimization of the assay, unlike of the experience of GENEQUALITY ENaC-TYPE 
development, has taken long time. The most critical issue was the randomly failure of 
HCV RNA identification in several samples. Step by step, we have analyzed all the 
possible reasons and focused our attention on RT-PCR efficiency, probably limited by 
the first set of primers designed. 
A more accurate selection of the primers have led to better results, suitable for 
diagnostic purpose. For performance evaluation of our HCV genotyping assay a set of 
220 samples were used. 
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Our assay showed a diagnostic specificity of 100% and a diagnostic sensitivity of 98.6% 
both at genotype and subtype levels. 
Results were compared with two reference methods: a CE-IVD assay that target the sole 
5’UTR and NS5b sequencing. As confirmed by NS5b sequencing, our test using a 
combined analysis of 5’UTR and core regions was able to correctly genotype all the 
samples. Conversely, the analysis of the sole 5’UTR has showed  mistyping of genotype 
6 samples. As reported in literature, this region is not able alone to recognize genotype 
6, subtypes c to n, and to differentiate them from genotype 1 [114]. 
This kind of mistyping could affect the management of therapeutic regimen. Indeed, SVR 
rates for genotypes 5 and 6 with PEG-based therapy are minor than SVR for genotypes 
2 and 3, but major than SVR for genotype 1. Dose of drugs is the same for genotypes 1 
and 6, but duration is lesser for genotype 6. On the other hand, clinical studies about 
administration of new DAAs to patients infected with genotype 6 are very few. 
Knowledge about efficacy, adverse effects, resistant profiles of strains are very limited. 
The major part of available DAAs shows a great efficacy against only genotype 1 strains. 
Among new DAAs, only sofosbuvir (Gilead) has been tested on patients infected by 
genotype 6 HCV (NEUTRINO clinical study) and can be used in the clinical practice. 
Therefore, misdiagnosis of a genotype 6 HCV in a genotype 1 could led to administration 
of a not adequate therapy, with risk for patient health. 
At subtype level, NS5b sequencing confirmed that our assay had correctly assigned the 
subtype to all samples infected with genotype 1. Instead, the analysis of the sole 5’UTR 
showed discrepant results, mainly in the subtyping of 1a strains, confirming the findings 
reported in previous studies [111]. The 5’UTR was not able to subtype almost half of 
samples 1a and about 10% was misdiagnosed as 1b. Less critical was the mistyping in 
the 1b samples group, in which the discrepancy was 4%. 
Until the introduction of new DAAs in the clinical practice, HCV subtyping was not 
mandatory to define correct therapeutic approach. However, antivirals molecules, such 
telaprevir and boceprevir, have shown variable efficacies on subtypes 1a and 1b. 
Probably the genetic barrier and resistance profiles substantially differ between the 
various genotype 1 subtypes. For this reason, the correct identification of HCV subtypes 
1a and 1b become crucial in clinical trials assessing new HCV drugs in order to stratify 
and interpret efficacy and resistance data. Misdiagnosis between subtypes 1a and 1b 
could led to application of a not appropriate therapy, causing failure of SVR and selection 
of resistant strains. 
The good subtyping results obtained by our test, confirm that RLB assay is an ideal tool 
for HCV genotyping. It is a simple and fast method and exhibits a high sensitivity and 
specificity. The same detailed genotyping information could be achieved with Real-Time 
technologies, but is necessary performing multiple amplification reactions for each 
sample. Instead, RLB allows the acquisition of a lot of sequence information in a single 
run. RLB is also the ideal technology for identification of co-infections by different HCV 
strains. NS5b sequencing can give a definite result for genotype but evaluation of more 
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HCV isolates presence in the same sample is very difficult. On the other hand, a critical 
issue of our test could be the results interpretation that required the careful use of an 
interpretation table, in which more than 90 different patterns are reported. For this 
reason, our study probably will continue with the implementation of an interpretative 
software tool. 
In conclusion, this work has demonstrated that RLB is a robust method for the 
management of several diseases, requiring a genetic characterization. However, genetic 
knowledge about target disorders must to be well defined. 
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